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Abstract 
Interaction of non-thermal, non-cavitational 20-100 kHz ultrasound and biological 
tissue: modeling and experimental validation 
 
Christopher R. Bawiec 
 
 
The primary goal of this work was to develop and verify a semi-empirical model that is 
capable of elucidating the mechanisms of interaction between low frequency (20 kHz), 
low pressure amplitude (55 kPa peak-peak) - corresponding to intensity equal to100 
mW/cm2 ((ISPTP), spatial peak, temporal peak) - ultrasound and biological tissue.  The 
novelty of this experimentally confirmed investigation is that it is the first relevant 
systematic approach examining such interaction.  The interaction is of substantial clinical 
importance as it enables wound management (accelerated healing of chronic wounds) and 
non-invasive transdermal drug delivery at ultrasound energy levels, which are considered 
safe for prolonged exposure by the FDA.   Specifically, as evidenced in the following the 
intentional use of low-intensity of 100 mW/cm2, spatial-peak temporal-peak (ISPTP), rules 
out potentially hazardous mechanisms of interaction such as inertial cavitation and 
thermal heating.  Modeling and experimental verification were based on the novel design 
of a lightweight (<100g), fully wearable, tether-free, and rechargeable battery powered 
ultrasound applicator that enables safe outpatient care.  Furthermore, this thesis 
contributed to enhanced understanding of the mechanical forces generated by the 
xvi 
 
applicator and the analysis procedure developed permits an estimation of the magnitude 
of these forces generated within tissue. The outcome of the modeling indicates that the 
possible mechanisms of action are most likely associated with non-thermal, non-inertial 
cavitational effects.  The in vitro and in vivo results of this study corroborate that the 
ultrasound applicator developed is capable of accelerating the healing process of chronic 
wounds, such as venous- and diabetic ulcers and can also enhance the efficiency of 
noninvasive, transdermal delivery of topically applied drugs.
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Chapter 1: Introduction 
The primary goal of this work was to develop and verify a semi-empirical model that is 
capable of elucidating the mechanisms of interaction between low frequency (20 kHz), 
low pressure amplitude (55 kPa peak-peak) - corresponding to intensity equal to100 
mW/cm2 ((ISPTP), spatial peak, temporal peak) - ultrasound and biological tissue.  The 
novelty of this experimentally confirmed investigation is that it is the first relevant 
systematic approach examining such interaction.  The interaction is of substantial clinical 
importance as it enables wound management (accelerated healing of chronic wounds) and 
non-invasive transdermal drug delivery at ultrasound energy levels, which are considered 
safe for prolonged exposure by the FDA.   Specifically, as evidenced in the following the 
intentional use of low-intensity of 100 mW/cm2, spatial-peak temporal-peak (ISPTP), rules 
out potentially hazardous mechanisms of interaction such as inertial cavitation and 
thermal heating.  Modeling and experimental verification were based on the novel design 
of a lightweight (<100g), fully wearable, tether-free, and rechargeable battery powered 
ultrasound applicator that enables safe outpatient care.  
The benefits of this design are multifaceted including potential benefits for patients, 
healthcare professionals, and insurance companies.  For patients, this device offers the 
opportunity of accelerating the rate at which their wounds heal.  This would have a 
substantial effect on a patient’s quality of life as not only would it alleviate the 
discomfort from having a chronic wound but also would save home-clinic- or point-of-
care transportation time and cost.  As for healthcare professionals, this device has been 
designed to be truly wearable and portable allowing for at home use by the patient.  
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Combined with the anticipated travel time savings this would free up valuable time for 
the clinician and increase patient compliance, which in turn, would lead to happier 
patients and healthcare professionals.  As for reducing the cost of patient care, this device 
not only accelerates the process of wounds healing (less time treating computes to less 
expense) but also has a potential for syringe-free drug delivery. Such application could 
help in shielding the patients with often compromised immune systems from a hospital 
visit, thus reducing or even eliminating the risk of contracting the infection.  Finally, 
determination of the mechanisms governing the healing and transdermal drug delivery 
processes could pave way to other applications in which external biomodulation (here 
ultrasound stimulus) is needed to activate biological response on the cellular level.  
The mechanical forces involved in the ultrasound tissue interaction have been identified 
and quantified providing the framework for creating an optimum ultrasound exposure 
matrix for clinically applied chronic wound care. In addition, the simulations performed 
have helped to elucidate the forces occurring at tissue interfaces; this in turn allowed the 
creation of a model that could be expanded upon in the future for further optimization of 
the device for the applications of wound healing and transdermal drug delivery.  
This thesis is organized in the following manner.  In the remainder of this chapter, the 
specific aims are enumerated and a flow diagram (Figure 1) identifying the scope of this 
work is shown. 
 Following the specific aims, Chapter 2 focuses on the background and significance of 
both chronic wound healing and transdermal delivery of drugs. Chapter 3 focuses on  
Aim 1, which was the Finite Element Analysis (FEA) of the ultrasound applicator’s 
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transducer for optimization and verification.  Chapter 4 presents FEA simulations, 
utilizing the model developed in Aim 1, for in vivo and in vitro setups.  Chapter 5 
presents results from experimental testing for cavitation, in vitro (fibroblast cell) 
exposure, and in vivo (human patients) wound treatment.  Chapter 6 presents a 
transdermal drug delivery study that provides evidence for potential syringe-free drug 
delivery, which could help in shielding the patients with often compromised or lowered 
immune system from a hospital visit, thus – as already noted above - lowering the risk of 
contracting the infection.  To close, Chapter 7 offers a summary of the current 
conclusions and proposed future work. 
1.1: Aim 1: Model the acoustic output of the ultrasound applicator using a Finite 
Element Analysis (FEA) approach and validate the results experimentally 
(COMSOL + lab experiments) 
Finite-element analysis software COMSOL Multiphysics was used to model the 
ultrasound applicator source with intentionally chosen flat geometry (see Figure 2).  The 
applicator employed conventional lead zirconate titanate (PZT) ceramic sandwiched 
between shaped metal caps.  Initially, the model was used to explore the effects of the 
ultrasound applicator’s architecture or geometry on the output resonance frequency and 
efficiency in terms of displacement amplitude for a given excitation (applied) voltage.  
The optimal geometric parameters for a given design were identified and an experimental 
validation that simulates clinically relevant exposure conditions was performed by 
measuring in-house fabricated devices with commercially acquired, calibrated (in V/Pa) 
hydrophones through both water and tissue mimicking (Polyvinyl Alcohol, PVA) 
phantoms.  
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1.2: Aim 2: Using the displacement amplitude data obtained in Aim 1 as input, 
quantify the effect of the ultrasound field parameters on tissue for the biological 
model considered.  (MATLAB + COMSOL) 
Experimentally obtained data (pressure vs. time data points) were used as input to the 
model to identify mechanical forces involved in the ultrasound-tissue boundary 
interaction.  Once the lack of thermal effects and inertial cavitation effects was verified 
(Aim 3, Chapter 5), a model (modified Rayleigh-Plesset, discussed in Chapter 4 below) 
that was suitable for the characterization of stable cavitation and associated phenomena 
was used.  The phenomena explored included acoustic streaming and acoustic radiation 
force.  Also, the applicability of a model (Kimmel-Krasovitzky, discussed in Chapter 4) 
that does not require the existence of microbubbles (or air voids) within the coupling 
layer between the ultrasound source surface and skin tissue, was examined.  
1.3: Aim 3: Experimental validation of ultrasound efficacy in accelerated wound 
healing (in vivo and in vitro experiments) 
As already noted, the experimental validation of the ultrasound-induced effects was 
carried out to verify that the exposure parameters considered here excluded inertial 
cavitation and thermal effects.  Well accepted physical and chemical tests (aluminum foil 
pitting and Terephthalic acid assay) for testing the presence of inertial cavitation were 
performed.   
In vitro verification of the ultrasound applicators’ ability to stimulate an advantageous 
biological response was done by examining the effect of ultrasound exposure on 
fibroblast cells, due to these cells documented role in wound healing [1-2].  The cells 
were cultured in plates and their response to the ultrasound application was investigated 
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using cellular assays, alamarBlue and BrDU, that indicate increased cellular metabolism 
and proliferation, respectively.  Increased proliferation of the cells was considered as a 
plausible indicator of potentially beneficial therapeutic effect.  
The tissue or in vivo effects were explored by examining the effects of ultrasound 
exposure on venous ulcers in human patients.  The anticipated end-point was accelerated 
rate of wound closure (in comparison with sham-exposed patients).  More specifically, 
wound size or area was monitored and was shown to decrease more rapidly with 
ultrasound treatment.  
 
Figure 1: Flow diagram of work described for Aims 1-3.  The three main components consist of mathematical 
modeling using MATLAB, finite-element modeling using COMSOL Multiphysics, and experimental validation 
of the results of the modeling. 
 
1.4: Aim 4: Experimental validation of improved transdermal drug delivery using 
the ultrasound applicator  
Experimental validation of improved transdermal drug delivery using the ultrasound 
applicator was performed in collaboration between Drexel University, Hebrew 
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University, and the Children’s Hospital of Pennsylvania.  Briefly, this experiment 
examined the effects of insonification implemented using the ultrasound applicator 
(Figure 2) on carrageenan induced inflammation in mouse paws.  Both ultrasound 
exposure alone and ultrasound exposure with concurrent application of topical drugs was 
investigated and compared with controls.   
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Chapter 2: Background and Significance – Problem  
Statement – Chronic Wounds and Drug Delivery 
The motivation behind this work was the unmet clinical need of accelerating healing of 
chronic wounds as well as identification of a non-invasive method of delivering drugs 
transdermally.  In order to achieve this goal, the low frequency (20-100 kHz) low-
intensity (~100 mW/cm2) ultrasound applicator, shown in Figure 2 was developed and 
demonstrated to be capable of promoting accelerated wound healing and facilitated 
transdermal delivery of the drug betamethasone.  To gain insight into these two 
applications, this section is organized such that the general ultrasound-tissue interaction is 
discussed first. This is then followed by a more specific examination of the ultrasound 
exposure leading to wound healing and transdermal drug delivery.   
 
 
Figure 2: Light-weight, fully-wearable, ultrasound applicator that contains an array of four flexural transducer 
elements specifically modeled and designed to operate at ~20 kHz and 100 mW/cm2 spatial-peak, temporal-peak 
intensity, corresponding to 55 kPa pressure amplitude. The black box houses the battery and electronics with an 
ON/OFF switch and an LED.  
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DISCLAIMER: In the review below, there are two ultrasound intensities relevant: 
spatial-peak, temporal-average (ISPTA) and spatial-peak, temporal-peak (ISPTP); however 
they are not always distinguished and specified in the literature, hence for consistency all 
intensities cited throughout this proposal are spatial-peak temporal-peak unless otherwise 
indicated. 
2.1: Ultrasound-tissue interactions 
Ultrasound interaction with biological tissue can be classified into two broad categories: 
mechanical and thermal.  This work focuses on mechanical interactions with the 
ultrasound as, with the low-intensity levels (~100 mW/cm2) investigated here, it is likely 
that thermal effects can be excluded (verified in Chapter 5 – Aim 3).  In addition, this 
low-intensity also prevents the incidence of inertial cavitation (which was also validated 
– Aim 3).  Therefore, only the mechanical interactions, which include acoustic radiation 
force, stable cavitation, and shear stresses associated with acoustic streaming, were 
examined here [3].  
When investigating the cavitation mechanisms, two possible scenarios of ultrasound 
tissue interaction need to be considered.  In the first one, the tissue contains no gaseous 
pockets or “microbubbles” and in the other one, the tissue does contain these bubbles.  
There is evidence that tissues contain these gaseous pockets, or they can be created 
during exposure to ultrasound [4], and therefore it is necessary to investigate the 
ultrasound interaction in both of these scenarios. The acoustic radiation force, which can 
be thought of a physical force that acts upon objects in the ultrasound wave’s path [5], 
does not require the existence of bubbles within the medium.  Stable and inertial 
cavitation do involve interaction of gaseous bodies with ultrasound waves, and as 
9 
 
identifying the role of stable cavitation was of interest, it is relevant to briefly discuss it in 
more detail.  Stable cavitation refers to a bubble (or air void) in a medium oscillating 
about an equilibrium radius; it does not lead to a violent implosion of the gas bodies, 
which is referred to as inertial cavitation, but it can induce mechanical stress by setting up 
acoustic streaming [6-7]. Acoustic streaming can be described as a steady state flow 
induced by time varying ultrasound energy, which is capable of generating shear stresses 
in the vicinity of the membranes that, in turn, lead to pressure gradients that can perturb 
and even rupture the cell membrane [7].  
It should, however, be noted that acoustic streaming also occurs in the absence of bubbles 
in the media and thus needs to be examined in both cases as a likely mechanistic force.  
In the next sections clinical need and evidence supporting the role of low-intensity, low-
frequency ultrasound as an effective agent for generating beneficial biological effects is 
given. 
2.2: Chronic wound healing process  
Chronic wounds such as pressure sores, ischemic-, venous leg-, and diabetic foot ulcers 
constitute a major challenge in clinical practice.  There are approximately 5-7 million 
Americans afflicted with these types of wounds, with an annual treatment cost of more 
than 20 billion dollars, with a large percentage occurring in the growing elderly 
population [8].  Diabetes affects 13 million people every year (5.2% of the U.S. 
population) with approximately 650,000 new cases diagnosed annually [9]. It is estimated 
that 15% of diabetic patients will develop an ulcer of the feet or ankles at some time 
during their disease course.  In addition, the US cost of managing pressure ulcers is 
estimated to be about $1.4 billion annually.  This cost is likely to rise due to an aging 
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population, particularly the increase in the number of octogenarians [10].  It is estimated 
that approximately 1% of the total health care costs in the western world are likely to be 
used for management of chronic leg ulcers [11].  Hence, there is a well-defined need to 
develop a non-invasive low-cost, therapeutic treatment of chronic wounds and be able to 
reduce the current cost of their treatment.  The results of the clinical pilot study discussed  
in Chapter 5 indicate that non-invasive ultrasound treatment offers one such less 
expensive approach.  In addition, due to portability of the patch-like applicator (Figure 2), 
a more patient -convenient solution resulting in more effective healing was made 
available.  
To provide background needed to better understand the complexity of interaction 
between ultrasound energy level used in this study and the biological end-points observed 
(wound healing and drug delivery) it might be helpful to discuss the process of wound 
healing.  Wound healing involves three overlapping stages: inflammatory phase, 
proliferation phase, and remodeling phase [10]. The inflammatory phase occurs 
immediately upon tissue injury and lasts from two to five days.  The purpose of this 
phase is solely to clean the wound debris.  The proliferative phase is characterized by 
fibroblast and epithelial cell proliferation and granulation tissue formation.  During the 
third (remodeling) phase, tissue remodeling, extra cellular matrix (ECM) restoration, 
epithelial cell turnover and wound contraction occur and complete the wound healing 
process.  In impaired healing environments, such as in chronic wounds, wounds are 
stagnated in the inflammatory phase, never progressing fully to the proliferative and 
granulation phase [12].  
11 
 
Ultrasound as a wound healing therapeutic modality  
It is well established that ultrasound energy can have beneficial influence on tissue 
healing, including wound healing [13-15], bone repair[16-18], and cell proliferation [19]. 
However, most  of the previously published data concerned with ultrasound assisted 
tissue healing were obtained at frequencies between 0.75 and 3 MHz and intensity levels 
that were often much higher than the Isptp intensity of 100 mW/cm2 employed here.  As 
noted earlier, the intensity level of 100 mW/cm2 is widely accepted as being safe even 
during prolonged exposure [20].  Accordingly, relevant articles cited in the brief review 
that follows were chosen based on the following criteria: they considered the exposure of 
tissue to ultrasound parameters that were similar (i.e. as close as possible) to those 
examined in this work; these parameters include intensity levels, frequencies and 
exposure time. A few publications, which did not comply with these criteria but offered a 
plausible discussion on possible mechanisms of interaction of ultrasound and tissue were 
also included.  The analysis of this review led to the initial selection of 10-100 kHz 
frequencies and 55 kPa pressure amplitude as preferred ultrasound treatment parameters 
that would eliminate that temperature- and inertial cavitation related effects.  
Peschen et al [15] reported that applying continuous ultrasound for 10 min during foot 
bathing at 30 kHz and 100 mW/cm2 three times a week enhanced the rate of wound 
healing in chronic venous leg ulcers.  After 12 weeks of treatment the control group 
showed a mean decrease of 16.5% in the ulcerated area, compared to a decrease of 55.4% 
in the 24 patients exposed to ultrasound (p<0.007).  In a different in vitro study both low 
(45 kHz, 15-30 mW/cm2) and high (1 MHz, 0.1-4 W/cm2) frequency, intensity ultrasound 
stimulated growth of fibroblasts and cytokine synthesis, but only the 45kHz frequency 
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exposure resulted in increased rate of collagen synthesis.  The 1 MHz ultrasound was 
pulsed with a duty cycle of 25% whereas the 45 kHz transducer was used in a continuous 
mode for 5 minutes [19].  This in vitro study supports the methodology of determining 
what mechanisms are responsible for accelerated wound healing.  Previous studies on rats 
with acute wound skin lesions performed by Young and Dyson [14] at frequencies of 750 
kHz and 3 MHz suggested that an intensity of 100 mW/cm2 could be useful in 
accelerating the inflammatory and early proliferative stages of repair in wounds. It is also 
important to point out that the 750 kHz ultrasound resulted in faster healing rates 
compared to those obtained using the higher frequency (3 MHz) [14].  The studies 
described in [14] ruled out thermal effects (<1˚C rise) and attributed the effectiveness of 
ultrasound to permeability changes and liberation of growth factors (such as VEGF) that 
could act as mediators of tissue repair in wounds.  
2.3: Transdermal drug delivery 
The advantages that transdermal drug delivery offers over intravenous and oral 
dispensing methods include avoiding invasive, often painful subcutaneous injection and 
avoiding a delivery mechanism for drugs which are prematurely metabolized by the liver 
when taken orally [21]. The current major disadvantage of transdermal drug delivery, 
caused by the structure of the epidermis, involves the inability or prohibitively slow (.04-
.08% in 12 hours) delivery of high molecular weight (MW>500 Da) or hydrophilic 
molecules [22]. As summarized below using low frequency, low-intensity ultrasound 
methodology may offer a truly portable, wearable, non-invasive transdermal delivery 
system.  
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Ultrasound assisted drug delivery  
Ultrasound energy, particularly that delivered at low kilo-Hertz frequencies (20–100 
kHz), has been shown to enhance skin permeability, a phenomenon called sonophoresis 
[23]. The efficacy of sonophoresis in delivering large-molecular weight substances 
(MW>5000 Da), such as insulin through the human cadaver skin, has also been 
demonstrated by Mitragotri et al in [24].  These experiments were performed at 20 kHz 
with intensity levels between 12.5 and 225 mW/cm2 (although the type of intensity was 
not reported). The suggested key mechanism of [24], responsible for the delivery, was 
stable cavitation of air pockets present in keratinocytes located in the stratum corneum.  
Stable (steady oscillations) and inertial cavitation (violent growth and collapse) of 
oscillating microbubbles could both play a role in the delivery described in [24] although 
it is impossible to tell which one with the information given.  
In this context it is appropriate to point out that the ultrasound/tissue experiments 
described in the literature – in general - lack sufficient exposure condition details that 
would permit the unequivocal quantified link between the ultrasound parameters included 
in the publication and the biological end-point observed. The lack of standardization of 
these data also makes an immediate comparison of the results arduous, if not impossible. 
More often than not the generic “intensity” value is given.  Strictly speaking there are at 
least four descriptions of the intensity parameter depending on the spatial and temporal 
conditions of exposure.  Such generic information is dubious and contains little, if any 
scientific value.  This is because it refers to a derived parameter (intensity) and because 
the derivation is only valid under far-field conditions.  The far-field condition (where 
particle velocity and pressure are in phase) is rarely met in the literature where, the far 
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field is located at an axial distance that is proportional to the frequency.  For instance, 
none of these conditions was met for the experimental setups described in [24-26].  
Accordingly, in this study, as described in the Chapter 5, the primary, governing 
parameter was chosen to be pressure amplitude measured at the axial distance 
corresponding to the clinical exposure distance.   
There is one relevant comparable work for transdermal delivery using the exposure 
conditions used here.  Researchers at Penn State reported insulin particles (molecular 
weight of about ~6,000 Da) being transdermally delivered using 20 kHz ultrasound 
source similar to the one proposed here (but with bulky electronics) [27].  They showed 
that this technology has potential to work for larger drugs (~6000 Da) at intensities of 
100 mW/cm2 ISPTP, far below the threshold of inertial cavitation.  
A few additional publications relevant to the experiments described in Chapter 5 are 
summarized below. However, most of these were performed at “intensity” levels that 
were substantially higher than these used in this study.  In this context, it is likely that the 
inertial cavitation induced sonophoresis was present.  
Formation of localized transport regions (LTRs) in the stratum corneum was proposed as 
the mechanism for transport of high (>500Da) molecular weight drugs by both 
Mitragotri’s [28] and Langer’s [25] group. Their work supported the idea that ultrasound 
induces dilatation and promotes connectivity of voids in the stratum corneum (SC); most 
likely leading to formation of a 3-D porous networks (LTRs), which are capable of 
transporting macromolecules across the SC.  The experiments  investigating these 
transport regions [25] describe the basic principle of transport in low-frequency (<100 
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kHz) sonophoresis being due to inertial cavitation (perhaps through microjets at skin 
surface) with intensities greater than 1 W/cm2. However, the studies [24] and  [25] also 
provide evidence that much lower intensities (on the order of 100 mW/cm2) can also lead 
to the formation of LTRs. Similarly, in a 2006 study, unfocused ultrasound at 20 kHz and 
spatial-peak temporal-average intensity level of 0.13 W/cm2, was found to be more 
effective in causing leakage from phospholipid vesicles than a 1.6 MHz focused 
ultrasound field at an intensity of 46.9 W/cm2 [29]. Also, the results of [26] pointed out 
that the cavitation threshold decreases with decreasing frequency; it was observed that at 
20 kHz and an intensity level of 125 mW/cm2 (type of intensity not specified), 
transdermal drug transport was up to 1000 times more effective in comparison with 
conventional, high (1-3 MHz) frequency field. The authors of [26] ascribed this 
enhancement to cavitation (without specifying whether stable or inertial), which induced 
bilayer disordering and facilitated the crossing of a hydrophilic drug or molecule. The 
limited research cited above corroborates the choice of the parameters used in this study 
(i.e. low-frequency (20-100 kHz) and low- pressure amplitude of 55 kPa corresponding to 
spatial peak temporal peak intensity of 100 mW/cm2). 
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Chapter 3: Aim 1: FEA model of the ultrasound applicator’s flexural transducer 
element and experimental validation 
3.1: Introduction: Model the acoustic output of the ultrasound applicator using finite 
element analysis (FEA) approach and validate the results experimentally (COMSOL + lab 
experiments)  
Parts of the following chapter were taken verbatim from the pre-published version of our 
research team’s first authored manuscript titled “Finite Element Static Displacement 
Optimization of 20-100 kHz flexural transducers for fully portable ultrasound 
applicator.”  This manuscript was accepted for publication in the journal “Ultrasonics” on 
September 6th, 2012 [30]. This chapter also contains original, previously unpublished, 
data that resulted from this work. 
3.2: Ultrasound applicator (history and description) 
In the previously published paper by our research team [31], the implementation of an 
early clinically relevant ultrasound applicator prototype, designed with the preliminary 
results of the proceeding modeling procedure, was described along with the motivation 
leading to the specific design parameters.  These design parameters include frequency 
range (20-100 kHz), acoustic output (≤ 100 mW/cm2 ISPTP), geometry (flat, < 10 mm 
thickness), lightweight (< 100 g), and Li-Polymer battery (≤ 15 V) operation.  For the 
convenience of the reader, the motivation is saliently summarized below and the seminal 
papers related to the applications considered, namely wound healing and transdermal 
drug delivery, are pointed out.  The pioneering work of Pennsylvania State University 
scholars on the flexural transducer design (Newnham, Tressler, Dogan et al. [32-35]) 
which formed the basis on which the optimization modeling was performed is 
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acknowledged.  The difference between the optimized applicator design described here 
and the cymbal transducers developed by the Pennsylvania State University research 
team is also analyzed in more detail. 
This chapter focuses on the development of a finite-element model and its subsequent 
stationary analysis performed to optimize individual flexural piezoelectric elements for 
operation in the frequency range of 20-100 kHz.  These elements form the basic building 
blocks of an un-tethered, and portable ultrasound applicator (example shown below in 
Figure 8-a) that can produce intensities on the order of 100 mW/cm2 spatial-peak 
temporal-peak (ISPTP) with minimum (approximately 15 V) excitation voltage.  The 
ultrasound applicator can be constructed with different numbers of individual transducer 
elements and different geometries such that its footprint (10x10 mm to 60x60 mm or 
more) and active area is adjustable.  As already mentioned, the primary motivation 
behind this research was to develop a tether-free battery operated ultrasound applicator 
for therapeutic applications such as wound healing and non-invasive transdermal delivery 
of both naked and encapsulated drugs [36-39].  The most promising results were reported 
in [39], where 20 kHz ultrasound pulsed with 20% duty-cycle at intensity levels less than 
100 mW/cm2 was employed in successful, in vivo transdermal insulin delivery, with a 
similar albeit bulky and non-portable ultrasound assisted delivery system.  
The flexural transducer elements that were optimized in this work were originally 
proposed by Newnham [33] in 1991 and were analyzed by Tressler in his comprehensive 
Ph.D. dissertation [35].  They were selected for displacement optimization in this work 
because they are capable of operation in the frequency bandwidth that is of interest here 
and their geometry lends itself well for fabrication of a flat (< 10 mm) patch-like 
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applicator that can be driven by a battery operated power source [31].  The interest in 20-
100 kHz frequency range stems from the extensive analysis of data published by 
Mitragotri and colleagues in Dr. Langer’s laboratory at MIT [40-44] and was already 
discussed in the previous chapter. 
In order to experimentally verify the model proposed here several early prototypes of the 
flexural transducer were fabricated with geometric dimensions and material properties 
that were determined by finite element analysis to have fundamental resonance 
frequencies on the order of 20 kHz.   
As already noted, the early (clinically applicable) prototype described in [31] was 
fabricated using the preliminary results of the model described below.  As discussed in 
the following, there are several geometric parameter combinations that can produce a 
specific resonance frequency and in order to minimize power requirements, it was 
necessary to determine the geometry that would result in the largest displacement 
amplitude for a given excitation voltage.  By minimizing the power requirements it was 
possible to reduce the battery size required to operate the device, thus reducing the 
overall weight of the applicator.  In the next subsection, the basic FEA (COMSOL) 
implementation principles are reviewed.  The review is given to aid in providing the 
background for understanding the fundamental limitations of the FE modeling.  
3.3: Finite element analysis (FEA) description 
FEA can be defined as a method that, utilizing computer software, allows numerical 
solving of complex partial differential equations that are used to describe the physical 
behavior of a modeled system.  FEA employs a system of points, referred to as nodes, 
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which are generated by a grid (mesh) that represents the geometry of a system.  This 
modeled system can then be analyzed after the appropriate assignment of material 
properties and boundary conditions and a prediction on the behavior of the overall system 
can be obtained.  As noted above, the structure being modeled is divided into a mesh of 
many elements, intersections of these elements are referred to as nodes and the analysis is 
run on each of the element’s nodes for the entire model.  As also mentioned earlier, the 
FEA of the flexural transducer used in the ultrasound applicator described here was 
performed using COMSOL Multiphysics software package version 4.2 with the MEMS 
and Acoustic modules.  The selection of COMSOL was arbitrary but version 4.2 allowed 
all of the parameters of interest to be considered.  Specifically, COMSOL version 4.2 
offers different types of analysis options for piezoelectric device simulations including 
eigenfrequency, frequency domain, stationary, and time-dependent analyses.  In the work 
reported here, eigenfrequency analysis was carried out in order to determine the 
resonance frequencies of the flexural transducer and frequency domain studies were used 
to compare the reactance spectra plots with both those available in the literature [34] and 
those obtained experimentally from the fabricated prototypes [31].  After experimental 
verification, stationary and eigenfrequency analyses were performed in order to optimize 
the applicator design.  Optimization is defined here as the largest possible displacement 
amplitude achievable for a given geometry and material combination for a given voltage 
applied at a specified frequency.  In the following, the FEA (COMSOL) procedure is 
outlined in more detail. 
The goal of this work was to develop and verify a practically convenient (fastest 
simulation time) finite element FEA model that would enable optimization of 20-100 kHz 
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ultrasound flexural transducers such as those used here.  Although COMSOL is capable 
of simulating mechanical systems dynamically using harmonic or time based analysis, the 
analysis presented in this chapter was performed based on stationary and eigenfrequency 
simulations as opposed to dynamic FE modeling (see Chapter 4).  This was done 
intentionally to reduce computation time and to limit the designs considered to those 
which resulted in the eigenfrequencies that were of potential interest for future dynamic 
studies.   
The outcome data of the static analyses were utilized to fabricate the early applicator 
prototypes [31], which operated at 20 kHz and with merely 15 V excitation were capable 
of producing the desirable, considered safe [45] acoustic peak-to-peak pressure output of 
55 kPa or about 100 mW/cm2 ISPTP. This 15 V is an order of magnitude lower than that 
reported earlier [35, 39] and permitted tether-free ultrasound applicator design.  
To gain additional understanding into the applicator optimization process, the static 
analysis was supplemented using eigenfrequency analysis, which allowed identification 
of the preferred resonance frequencies in air.  In the fabricated prototype [1], the air 
measured resonance frequency was shifted downward due to the mass loading effect of 
embedding epoxy [46].  The prototype design described in [31] exhibited resonance 
frequency equal to about 37 kHz in air – the resonance frequency of the final, epoxy 
embedded applicator of [31] was measured acoustically to be about 20 kHz. 
3.4: FEA procedure 
The three-dimensional exploded view of a single flexural element used in the ultrasound 
applicator is shown in Figure 8-a.  It is rotationally symmetric (to minimize the 
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simulation time) about its centerline and therefore lends itself well to two-dimensional 
axis symmetric modeling.  Accordingly, two-dimensional axisymmetric modeling was 
chosen as it allowed the high (1000 fold more time consuming) computational cost 
associated with three-dimensional modeling to be eliminated.  The components of the 
applicator that were considered in the systematic, step-by-step analysis can be divided 
into three broad categories: piezoelectric materials, adhesive epoxy, and shaped metal 
caps.  The physical properties of the metal and the piezoelectric materials that were 
modeled were taken from COMSOL’s material library. The adhesive epoxy material 
properties were obtained from the technical data sheet (Stycast 2741 LV / Catalyst 15 
LV, Emerson and Cuming) and the thickness was fixed to be 20 microns.  The reason for 
choosing this epoxy type was based on earlier published data [35]; Tressler suggested 
that the thickness of the bonding epoxy between the metal cap and the PZT ceramic was 
approximately 20 microns and at 20 kHz (corresponding wavelength 75 mm) it was 
acoustically transparent.  
The metal caps (brass) that were fabricated and modeled in this work were chosen to 
have the same overall radial dimensions as the PZT disks.  Due to manufacturing design 
constraints, (which required adequate bonding surface area for the metal caps to adhere to 
the PZT), in the simulations, the base radius of the shaped metal cap (Figure 8-a) was 
modeled such that there was at least a 1 mm ring of bonding surface between the PZT 
disk and the metal cap (bonding epoxy width).  The metal cap apex radius was modeled 
such that the difference between the apex radius and the base radius was at least 1 mm 
and this was done to ensure that the metal cap retained a “truncated cone” shape (Figure 
8-a) which was required for the desired flexural motion [35].  
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An important aspect of the FEA study was the assignment of appropriate structural and 
electrical boundary conditions.  Three structural boundary conditions were considered, 
one that fixed the model about its rotational axis, another that was applied along the 
horizontal center of the PZT disk (prohibiting rotational movement), and finally, the one 
ensuring "free" movement everywhere else.  The electrical boundary conditions were 
implemented by placing a voltage terminal on the top and a ground terminal on the 
bottom surface of the PZT disk, respectively. 
As pointed out earlier, in order to verify the model the initial finite element analysis was 
performed with the same geometric dimensions and materials as those reported in [34]. 
The analysis presented in [34] was performed using a different FEA software (ANSYS) 
and the comparison of the eigenfrequencies obtained using COMSOL and ANSYS 
corroborated the validity of the analysis applied.   
Further verification of the model was obtained by comparing simulated and experimental 
data. More specifically, the eigenfrequencies and the reactance spectra were modeled 
using the COMSOL software for a selected geometry, piezoelectric material, and 
adhesive epoxy.  Next,  the prototype, similar to the one described in [31], was fabricated 
and tested using AIM 4170C antenna analyzer (Array Solutions, Sunnyvale, Texas USA). 
The experimental (Figure 3) and simulated results (Figure 4) compared well (to within 
5%); this agreement was deemed sufficient to confirm the validity of the model.   
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Figure 3: Impedance measurements of a single element transducer generated using a spectrum analyzer.  This 
graph indicates that the resonance of the transducer measured was approximately 40 kHz.  
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Figure 4: Admittance spectrum of the ultrasound transducer generated using COMSOL showing a resonance 
near 40 kHz.  This simulation model matched the geometric dimensions of transducer that was experimentally 
measured in Figure 3.    
 
Another modeling outcome that was verified to ensure that the COMSOL model was 
representing the experimental data gathered using the actual transducer was a comparison 
of the pressure field distributions.  The pressure amplitude of the transducer was 
measured using a calibrated hollow cylinder hydrophone similar to that described in [47], 
and this hydrophone was used to obtain all the results presented in Figure 5.  This 
pressure field distribution was done by moving the hydrophone in 0.5 mm steps in an XY 
grid at an axial distance of ~2.5 mm away from the transducer face (to simulate the 
clinical exposure conditions).  For comparison, a COMSOL transducer model was built 
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that coupled the transducer to water so that pressure distribution in the water could be 
simulated.  These results also agreed well (to within 10%) with the experimental data, 
which can be seen by comparing Figure 5 and Figure 6.  Furthermore, the computer-
generated directivity pattern (Figure 7) of the transducer in this same model was obtained 
and it shows that the simulated data was adequately representing the fabricated models.  
  
 
Figure 5: 2D pressure distribution obtained at 2.5 mm from transducer face.  The spatial units are in 
millimeters. 
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Figure 6: Acoustic pressure distribution generated using COMSOL for a single element coupled to water. 
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Figure 7: Simulated directivity pattern (half) of a single element transducer.  This is the projection 
perpendicular to the face of the transducer     
 
Once the COMSOL model was verified, stationary and eigenfrequency analysis was 
performed on the flexural transducer model.  As already noted, the ultimate goal of the 
simulation was to determine the geometry and material components providing maximum 
pressure amplitude at a given frequency while using minimum voltage excitation.  The 
results presented below pertain to a design that operates at 20 kHz.  This frequency was 
initially chosen because it is the only frequency that was successfully used in vivo for 
transdermal non-invasive insulin delivery in piglets [39], however optimization results 
were also obtained for prototype designs operating at 100 kHz.  A frequency range (20 – 
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100 kHz) was investigated in order to have multiple designs such that the applicators’ 
clinical treatment efficacy (in relation to the frequency) and, if needed, could have been 
evaluated and optimized. In the following the results of analysis of the geometric and 
material parameters of the metal caps and the PZT are presented.  The geometric 
parameters of interest (Figure 8-a), which included those of the PZT disk (thickness and 
radius) and the metal cap (thickness, base radius, apex radius, and cavity depth), were 
also examined.  Analyses on the FEA model were performed varying all of the 
aforementioned geometric dimensions for both stationary and eigenfrequency analysis. 
The PZT type and the metal cap material were initially investigated for a constant 
geometry in order to determine their effects on the model simulation such that they could 
remain constant during the subsequent analyses.  After the modeling, components were 
analyzed and set to be PZT-4 (due to its relative availability and known transmitting 
properties) for the piezoelectric ceramic and brass for the metal end caps, the geometric 
parameters of interest were varied to obtain the optimized design (see modeling section 
for more details on material selection).  For the stationary studies a maximum axial 
displacement amplitude was determined at the center of each metal cap with 100 V 
applied. The voltage choice for this modeling was arbitrary as the results scale linearly 
with the applied voltage (the final fabricated prototype operated with 15V excitation 
[31]).  The modeling results are presented in the next section. 
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Figure 8: a) Three-dimensional exploded view of a single flexural element used in the ultrasound applicator (also 
shown in d).  b) Two-dimensional axisymmetric model with mesh used in FEA analysis.  c) Two-dimensional 
axisymmetric model with applied voltage excitation showing normalized displacement (displacement shown is 
not to scale). d) Ultrasound applicator prototype [31] (3x3 array configuration – dimensions of 55x55x8 mm). e) 
Photo showing applicator prototype being worn on the forearm (2x2 array configuration – dimensions of 
35x35x8 mm). f) Top-half two-dimensional slice of single flexural element used to facilitate interpretation of the 
results shown in Figure 9, Figure 10, Figure 11, Figure 12, Figure 13, Figure 14, and Figure 15.  Here the cavity 
depth is shown as an example; see also Figure 11       
 
3.5: Static FEA results:         
Below are detailed descriptions of the influence of each parameter’s geometry and 
material influence on the design optimization. 
Piezoelectric material type and thickness  
There are several different types of piezoelectric materials that are both naturally 
occurring and man-made.  Of these materials, only piezoelectric ceramics that were 
commercially available, relatively inexpensive, and easy to procure are analyzed here.  
Thus, PZT ceramics that were commercially available with relatively short lead times (< 
2 months) were analyzed.  It is conceivable that recent advances in composite ceramic 
b 
c 
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and single crystal ultrasound transducers could potentially provide a more optimized 
design alternative than the PZT ceramics described here [46, 48-49].  However, as 1-3 
composite PZT ceramics and single crystals are relatively expensive and difficult to 
procure they were not analyzed in the course of this work.  Also, due to a recent directive 
in the European Union attempting to phase out lead usage [50], lead-free ceramics that 
are currently under development [51] could potentially replace PZT ones; again, they 
were not investigated here.   
In order to determine the ideal PZT type it was necessary to examine the 
electromechanical properties of the PZT ceramics.  The piezoelectric ceramic 
manufacturers provide data sheets for the standard PZT types that they make along with 
explanations of the material properties.  As the displacement amplitude is primarily 
dependent upon the values of the d33 and d31 coefficients [32], PZT-4 was chosen as the 
PZT ceramic that was used in the analysis presented.  Since PZT-4 and PZT-8 are the 
commonly accepted transmitter type ceramics PZT-4 was found to be better suited 
(higher displacement for a given voltage) for this low-intensity (100 mW/cm2) flexural 
transducer application.  
The geometry of the PZT disk (thickness and radius) also determines the achievable 
displacement amplitude.  As shown in Figure 9 the displacement amplitude is inversely 
proportional to the PZT disk thickness for a given PZT disk radius.  For example with a 
10 mm radius PZT disk lowering the thickness from 3 mm to 0.5 mm results in a 4 fold 
displacement amplitude increase from approximately 3 µm to 12.5 µm.  Although the 
results of modeling show that 0.25 mm thickness would further increase the displacement 
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amplitude 0.5 mm thick disks were chosen to minimize the tradeoff between fragility 
(due to the brittle nature of the PZT) and mechanical compliance of the ceramic material.  
 
Figure 9: Influence of PZT disk thickness varying from 3 to 0.25 mm on relative displacement amplitude for 
PZT disk radii varying from 3 to 10 mm. As mentioned previously, the metal cap base radius was modeled such 
that its maximum value was always 1 mm less than that of the PZT disk (See text for details). 
 
Metal cap materials 
Influence of different metal cap materials on relative displacement amplitude compared 
for a constant geometry is shown in Figure 10.  A constant geometry (PZT disk radius: 6 
mm, base radius: 5 mm, apex radius: 1 mm, cavity depth: 0.2 mm, cap thickness: 0.125 
mm) was chosen for display of the analysis although other geometries were also analyzed 
and the trend was found to be similar for all of the metals considered.  For the modeling 
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condition shown in Figure 10 the maximum displacement amplitude was obtained for 
aluminum, however in the following analysis brass was used.  This was because the 
availability of brass and the relative ease of cutting and shaping the metal cap for 
experimental prototypes.   
 
Figure 10: Influence of different metal cap materials on relative displacement amplitude compared for a 
constant geometry (PZT disk radius: 6 mm, base radius: 5 mm, apex radius: 1 mm, cavity depth: 0.2 mm, cap 
thickness: 0.125 mm). 
 
Metal cap cavity depth and thickness  
The cavity depth in Figure 11 is defined as the distance between the PZT ceramic face 
and the apical planar region of the shaped metal cap (shown in Figure 8-e).  The 
displacement amplitude depends on the cavity depth for a given PZT radius and metal 
cap thickness and facilitates up to a three-fold increase in displacement amplitude for a 
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given PZT radius.  For example in Figure 11-a for a PZT radius of 10 mm there exists a 
peak in maximum displacement amplitude which was found to be 12+ µm at a cavity 
depth of approximately 0.175 mm.  The graphs (Figure 11-a and b) of cavity depth versus 
displacement amplitude illustrate that the maximum displacement amplitude appears at 
different cavity depths depending upon the thickness of the metal cap that is used.  The 
maximum displacement amplitude was obtained for dimensions of approximately 0.175 
mm cavity depth for metal cap thickness of 0.125 mm and approximately 0.325 mm 
cavity depth for metal cap thickness of 0.25 mm (the remaining geometric dimensions 
were fixed – see Figure 11 for details).  Inspection of Figure 11-a (metal cap thickness 
0.125 mm) and Figure 11-b (metal cap thickness 0.25 mm) reveals that with increasing 
thickness of the metal cap the cavity depth that is necessary for maximum displacement 
also increases.  It is worthy of noting that decreasing metal cap thickness from 0.3 mm to 
0.125 mm results in increasing of the displacement amplitude (Figure 12).  The analysis 
performed indicated that 0.125 mm thick metal caps were most practical for use in the 
prototype fabrication [31] because the sheets of 0.125 mm are commercially available. 
Also, the machining of the shaping die that was used for their fabrication was simplified. 
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Figure 11: Influence of metal cap cavity depth on the relative displacement amplitude for PZT disk radii 
varying from 3 to 10 mm for metal cap thickness of a) 0.125 mm and b) 0.25 mm.  These graphs show that the 
maximum displacement amplitude peak shifts from approximately 0.175 mm cavity depth for metal cap 
thickness of 0.125 mm to approximately 0.325 mm cavity depth for metal cap thickness of 0.25 mm. Also shown 
is the overall effect of metal cap thickness on the displacement amplitude; the maximum displacement amplitude 
increases from 4.5 µm with a metal cap thickness of 0.25 mm to over 12 µm with a metal cap thickness of 0.125 
mm.  
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Figure 12: Influence of metal cap thickness on relative displacement amplitude for PZT disk radii varying from 
3 to10 mm. This figure summarizes the data obtained for metal cap thickness ranging from 0.3 to 0.125 mm for 
a PZT radius varying from 3 to 10 mm.  To facilitate the fabrication process 0.125 mm thickness was chosen to 
be the thinnest metal cap modeled.  
 
Metal cap base and apex dimensions  
In addition to the PZT disk radius, the base radius of metal cap influences the 
displacement amplitude.  As shown in Figure 13, with increasing metal cap base radius 
(modeled from 2 to 9 mm) the maximum displacement amplitude also increases (from 
approximately 0.8 to 12+ µm, respectively).  The plots in Figure 13 overlap indicating 
that the metal cap base radius plays a more dominant role in comparison with the 
influence exerted by the PZT disk radius.  For instance, if the metal cap base radius were 
fixed at 2mm, with all other parameters constant, the maximum displacement amplitude 
would be within 5% for all PZT disk radii varying from 3 to 10 mm.  In Figure 13 the 
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apex radius was kept constant at 1 mm whereas the base diameter was varied from 2 to 9 
mm (always ensuring that it was 1 mm less than the PZT disk radius).  As previously 
mentioned, the reason for keeping the outer radius a minimum of 1 mm less than the PZT 
disk radius was to ensure that an adequate bounding surface was available for the 
adhesive epoxy to be applied during manufacturing.  Also, the choice for making the 
apex radius always 1 mm smaller than the base radius was to maintain the desired 
flexural motion which requires the metal cap to retain a “truncated cone” shape.  Figure 
14 depicts the influence of apex radius on the displacement amplitude and shows that the 
maximum value is dependent upon the PZT disk radius.  For the 10 mm and 3 mm disks 
the apex radius providing the maximum displacement is 2.25 mm and 0.75 mm, 
respectively.  However, as seen in Figure 14, there is less than 5% change in the 
maximum displacement amplitude as long as the apex radius is less than half of the base 
radius.  This is most clearly seen with the 10 mm PZT disk radius in Figure 14 where 
there is a near horizontal trend in displacement amplitude from 0.1-4.5 mm metal cap 
apex radius dimensions.   
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Figure 13: Influence of metal cap base radius on relative displacement amplitude for PZT disk radii varying 
from 3 to10 mm.  To facilitate fabrication and ensure adequate bonding surface for the adhesive epoxy the metal 
cap base radius was modeled such that its maximum value was set to be 1 mm less than the radius of the PZT 
disk.  The above results indicate that the displacement amplitude was controlled primarily by the metal cap base 
radius and not by the PZT disk radius (see text for further explanation).    
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Figure 14: Influence of metal cap apex radius on relative displacement amplitude for PZT disk radii varying 
from 3 to10 mm. In order to ensure flexural motion the metal cap needs to retain a “truncated cone” shape, 
therefore the metal cap apex radius was always set to be at least 1 mm less than the metal cap base radius.  
 
Operating frequency 
The last parameter considered for device optimization was frequency of operation.  Only 
designs that had their first eigenfrequency within 10% of the desired frequency of 
operation (i.e. 18-22 kHz for 20 kHz applicator and 90-110 kHz for the 100 kHz 
applicator) are displayed in Figure 15 and Table 1.  In the final prototype implementation 
mass loading effects of the potting epoxy can shift the resonance frequency by much 
more than 10%; as noted earlier in [31] a shift in resonance frequency from 37 kHz in air 
down to 20 kHz once the prototype was embedded in epoxy was observed.  It was 
determined experimentally that the resonance frequency was dependent upon the 
volumetric combination of the multi-component epoxy (Spurr’s epoxy).  Spurr’s epoxy 
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was selected here due to its proved performance in other piezoelectric ultrasound 
transducer designs (such as the composite transducer described in [46]) and the ability to 
adjust its “hardness”.  The influence of epoxy “hardness” on acoustic output and 
resonance frequency of the fabricated prototype is being investigated and the results 
should be presented in an upcoming publication from this group.   
Figure 15 displays a single, yet representative, example demonstrating the dependence of 
the resonance frequency on the geometric dimensions of the flexural transducer as a 
function of the cavity depth.  Resonance frequency analysis was run concurrently with 
stationary analysis on all of the models analyzed.  The models that generated resonance 
frequencies at 20 and 100 kHz were then selected and compared to determine the 
geometry that produced the maximum displacement amplitude at those frequencies. 
Although several geometries were capable of generating 20 and 100 kHz resonance 
frequencies, the specific dimensions shown in Figure 15 produced the maximum 
displacement amplitudes at both 20 and 100 kHz.  
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Figure 15: Resonance frequency vs. cavity depth of transducers with various PZT disk radii varying from 3 to 
10 mm. PZT with radii of 3 to 5 mm (a) were modeled with geometric dimensions for the metal cap base and 
apex radii of 2 and 0.75 mm, respectively, whereas PZT disk radii of 6 to 10 mm (b) have fixed metal cap base 
and apex radii of 5 and 1.75 mm, respectively.  The stars on lines a and b represent the optimal flexural 
transducer design geometry at the frequencies considered here (i.e. 20 and 100 kHz).  
 
For the 20 kHz design the FEA analysis indicated that the maximum displacement 
amplitude condition requires PZT disk radii to be at least 6 mm (6 to 10 mm radii were 
modeled here) with metal cap geometric dimensions of: base radius from 4.75 to 5.25 
mm, an apex radius from 1.5 to 2.0 mm, and a cavity depth from 0.25 to 0.30 mm.  For 
the described metal cap geometric dimensions the PZT disk radius had less than 5% 
effect on the displacement amplitude from 6 to 10 mm, however, when the radius became 
less than 5 mm the peak displacement amplitude started to decline.  In Figure 15 the 
dimensions that were selected show just a single geometry ensuring optimal displacement 
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(see also Table 1) and for a given frequency of operation (20 and 100 kHz) the 
displacement amplitude at those geometries was in the top 5% of the amplitudes for all 
the models investigated.  For the 100 kHz design the optimal dimensions were 
determined to be 3 to 5 mm for the PZT disk radii with a metal cap base radius between 2 
and 2.25 mm, a metal cap apex radius between 0.5 and 0.75 mm, and a cavity depth from 
0.225 to 0.325 mm.  Again, the PZT disk radius had less than a 5% effect on the 
displacement amplitude for 3 to 5 mm PZT disk radii when the metal cap was fixed at the 
above mentioned geometric dimensions, and smaller PZT disk radii were not modeled.  
As indicated in Figure 8-d the ultrasound applicator is primarily operated as arrays of 
elements and therefore the smallest PZT disk radius that could produce the desired 
displacement amplitude at the desired frequency should have been chosen.  However,  
due to commercial availability of the PZT disks as well as the machining tools, the 
experimental verification of the prototype described in [31] used PZT disks having 6.35 
mm radius (1/2” diameter). 
 PZT Dimensions (mm) Metal Cap Dimensions (mm) 
Resonance 
Frequency Radius Thickness 
Base 
Radius 
Apex 
Radius 
Cavity 
Depth Thickness 
20 kHz 6-10 0.5 5 1.75 .275 0.125 
100 kHz 3-5 0.5 2 0.75 .075 0.125 
Table 1: Dimensions for manufacturing an optimized flexural transducer element operating at 20 and 100 kHz. 
 
3.6: Conclusions 
Systematic step-by-step finite element analysis leading to the optimization of a clinically 
relevant prototype of light weight (<100g) flexural ultrasound applicator used in this 
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study was described.  The results of this research provide guidelines for optimization of 
the applicator design examined and indicate that consideration of the ceramic properties 
may further improve its performance.  Additional (slightly less than 10 %) improvement 
could also be achieved if brass is replaced with aluminum (see Figure 10).  As noted 
earlier it is conceivable that replacing conventional PZT materials with PZT composites 
or single crystals could further enhance the applicator’s acoustic output.  Also, in light of 
the recent developments in lead-free piezoelectric ceramics [51], it is plausible that 
medical devices may require the incorporation of these ceramics in the future [50].  As 
these ceramics’ electromechanical parameters are in general lower than those of PZT 
ceramics, future studies might be needed to determine the effect of lead-free ceramics on 
the ultrasound applicator’s acoustic output. 
As already mentioned, the work on this Aim (Aim 1, Chapter 3) resulted in the 
publication "Finite Element Static Displacement Optimization of 20-100 kHz flexural 
transducers for fully portable ultrasound applicator" in Ultrasonics in 2012.  This 
completed ultrasound applicator model also provided the framework for the acoustic 
output model that was used in Aim 2 (Chapter 4) for identifying and quantifying the 
forces associated with ultrasound tissue interaction. 
  
43 
 
Chapter 4: Aim 2: Quantification of the ultrasonic forces on biological tissue. 
4.1: Introduction: Use the displacement amplitude data obtained in Aim 1 as input 
to quantify the potential effect of the ultrasound field parameters on tissue for 
biological models considered.  (MATLAB + COMSOL) 
The primary focus of this aim was to implement and investigate mathematical and FEA 
models that can help to elucidate the magnitude of ultrasound forces that are effecting  
biological tissue and/or cells depending on the exposure conditions and geometry with 
the ultrasound applicator discussed here.  The COMSOL model that was discussed in 
Aim 1 (Chapter 3) was modified to incorporate the application area (cell plates and 
biological tissue) into the model.  These different models represent the use of the 
applicator at the tissue interface (in vivo simulation) and the applicator being used on the 
cells in culture (in vitro simulation).  In addition to the determining the forces in effect 
with the tissue, the in vitro test setups were also investigated in order to facilitate 
comparisons.   
The COMSOL models provided the pressure amplitude versus time data within- and 
surrounding the tissue whereas the  mathematical models implemented in MATLAB 
were used in order to understand the first and second order forces caused by the 
ultrasound pressure waves.  A Wrenn modified Rayleigh-Plesset model of bubble 
dynamics [52] , which accounts for the forces associated with existing microbubbles in 
the stratum corneum as well as the tissue interface was implemented.  Also,  the 
Krasovitzky-Kimmel (KK) model [53] of lipid bilayer destruction was examined. This 
model was used to quantify the forces in the situation where only dissolved gases (but 
not-bubbles or air voids) are present in and around the tissue. This model – as advised 
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earlier in Chapter 1 - provided a mechanism of cellular interaction that does not rely upon 
the existence of microbubbles.  The combination of Wrenn and KK models made it 
possible to quantify the radiation force and shear stress that occurs with the ultrasound 
source in a medium that does not contain free air bubbles.  This was necessary since 
having bubbles in the medium versus a bubble-free medium yields different forces.  The 
advantages of these models are that they provided quantitative approximations of the 
forces generated from the ultrasound device, which in the future, should aid in analysis of 
the mechanisms of action in both wound healing and transdermal drug delivery.  The 
disadvantage of these models was that they are “models” and they do not represent all of 
the complexities of biological interactions (protein interactions, cellular signaling, etc.).  
As the proposed ultrasound applicator has been intentionally designed to operate at FDA 
approved intensity levels for long-term exposure according to the 2008 Statement on 
Mammalian In Vivo Ultrasonic Biological Effects from the American Institute of 
Ultrasound in Medicine [20], it was anticipated that it would not generate inertial 
cavitation events (which was verified in Aim 3 - Chapter 5).  Such cavitation would 
introduce potentially undesirable side effects because imploding bubbles generate 
localized shock waves. These shock waves exhibit compressional pressure amplitudes on 
the order of 100 MPa and associated temperature elevation of approximately 5000˚K 
along with free radical (OH-) formation.  As already noted the applicator’s acoustic 
output was intentionally limited to prevent the possibility of introducing inertial 
cavitation effects.  Indeed, the experimental data presented in Chapter 5 confirmed that 
the ultrasound related forces can be ascribed only to “non thermal, non inertial 
cavitational” effects, such as radiation force, stable cavitation with an associated acoustic 
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streaming and viscoelastic stresses. In order to quantify these effects, FEA simulations 
were run and mathematical models were used.  
The remainder of this chapter is organized in the following way. First, the FEA model of 
the ultrasound transducer developed in Chapter 3 was expanded, coupling the ultrasound 
applicator element to in vitro testing fixtures (Petri dishes), which mimicked the 
experimental conditions of the in vitro experiment performed with fibroblasts and 
described in Chapter 5.  Next, time domain analyses were performed on the models to 
obtain the pressure versus time output.  This output was then utilized to estimate the 
forces that occur at tissue boundaries using the ultrasound applicator studied here. 
Finally, the order of magnitude of normal forces and shear stresses acting on the skin 
boundary and showing comparisons of these values with those reported in the literature is 
listed in final section of this chapter (Section 4.7).  As alluded above two possible 
scenarios were suggested and explored in order to determine the mechanisms of 
interaction: the first with bubble-free medium (both the coupling gel and tissue) and the 
other with bubbles contained within the medium. 
4.2: In-vitro FEA models 
This section examines different FEA models that incorporate the ultrasound applicator 
described here used with in vitro setups (ultrasound transducer coupled to various cell 
culture dishes.  This was done to facilitate comparison between different testing setups 
and the experimental conditions in which the applicator was used here.  Although 
described in more detail in Chapter 5, briefly, ultrasound was applied using the applicator 
of Figure 2 to in vitro setups growing fibroblast cells and independently in vivo with 
humans.  The acoustic outputs were measured using a calibrated hydrophone (Reson 
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4038) to determine the ultrasound field distribution and pressure amplitude in a de-
ionized water tank at axial distances of 1-3 millimeters (representative of exposure 
practice or emulating clinical application).   
In the first FEA model analyzed in the time-domain, the ultrasound applicator was in free 
field conditions mimicking the experimental calibration setup (2D-axisymetric FEA 
schematic shown in Figure 16).  Next, the model was “calibrated” to ensure that the 
experimental results matched the modeled results in this scenario.  This “calibrated” 
model was then coupled to different test setup models with the same excitation 
parameters to facilitate comparison.  The remainder of the section addresses different 
scenarios that were modeled using this specific applicator in various in vitro conditions. 
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Figure 16: Transducer (quarter section of the applicator was used to minimize simulation time) operating in a 
free-field environment coupled to a homogeneous medium that does not reflect waves.  This configuration was 
used for calibration of the model with water as the medium and also for the tissue interaction. 
 
Applicator located underneath Petri dish (single well of a 6-well plate)    
The first scenario that was modeled is the setup in which the in vitro studies performed in 
Chapter 5 used.  This setup had the ultrasound applicator coupled to the bottom of the 
cell culture dish with culture medium (water modeled here) at 5 mm depth.  The reason 
that this application method was used experimentally, and subsequently modeled, was 
that it does not permit the contact of the cell media with the ultrasound applicator, which 
in turn limits possibility of contamination.  A picture of the setup is shown in Figure 17 
and the 2D-axisymetric schematic is shown in Figure 18.   
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Figure 17: In vitro test setup for fibroblast testing.  The transducer is coupled to the bottom of the a single well 
of a 6 well, flat bottom plate (Falcon® Multiwell Plates For Cell Culture, #353046) with ultrasound gel. 
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Figure 18: 2D-axisymetric schematic of In vitro test setup for fibroblast testing.  The transducer is coupled to the 
bottom of the well with ultrasound gel (see Figure 17). 
 
Applicator in contact with the media from above (single well of a 6-well plate)  
The next scenario that was modeled, considered the setup in which the ultrasound 
applicator was positioned to be in contact with the cell culture media (water modeled 
here).  In this scenario the applicator is suspended along the edges in contact with the 
media which is 5 mm deep (to simulate the experimental conditions described in Chapter 
5).  This method more closely resembles the clinical application conditions where the 
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applicator is coupled to the wound.  A picture of the setup is shown in Figure 19 and a 
2D-axisymetric schematic is shown in Figure 20. 
 
Figure 19: In vitro setup for application of the ultrasound from the top of the well.  The ultrasound applicator is 
in direct contact with the cell growth media. 
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Figure 20: 2D-axisymetric schematic of In vitro test setup for application of the ultrasound from the top of the 
well.  The ultrasound applicator is coupled directly to the cell growth media. 
 
Applicator in contact with the media from above (single well of a 6-well plate) 
coupled to a liquid to reduce reflections at plate boundary 
The final in vitro setup scenario that was modeled is one in which the ultrasound 
applicator was positioned to be in contact with the cell culture media (water modeled 
here) and additionally coupled to liquid below the plate.  In this scenario the applicator is 
also suspended above the bottom of the well, just in contact with the media which is 5 
mm depth.  The main difference with this method is that it even more closely matches 
certain clinical scenarios where the reflections from ultrasonic wave will not be occurring 
directly (within 1-2 mm) below the targeted cells.  A picture of this in vitro setup is 
shown in Figure 21 and a 2D-axisymetric schematic is shown in Figure 22.    
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Figure 21: In vitro test setup with 6-well plate coupled to liquid in 20 cm tall container in order to  reduce 
reflections.  The applicator is in direct contact with the cell media. 
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Figure 22: 2D-axisymetric schematic of in vitro test setup with 6-well plate coupled to liquid in 20 cm tall 
container in order to reduce reflections.  The applicator is in direct contact with the cell media. 
 
4.3: COMSOL output used as input to Wrenn modified Rayleigh Plesset model 
Utilizing the FEA models described above, pressure vs. time output data was acquired 
from the models in the center of the Petri dish (where the cells would be grown, or at one 
millimeter axial distance away from the transducer face in the case of the free field (in 
vivo) setup.  These pressure vs. time curves were determined by using COMSOL’s time 
dependent physics analysis where a time varying voltage was applied to the piezoelectric 
element to simulate the experimental conditions.  The voltage was determined by 
matching the simulated pressure output with the experimental conditions as can be seen 
in Figure 23, where the free field conditions, shown in Figure 16, provide a pressure 
amplitude of approximately 55 kPa and operation at 20 kHz.   
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Figure 23: Pressure vs. time wave form of time-dependent model shown in Figure 16, where no acoustic 
reflections are present. 
 
In Figure 24, Figure 25, and Figure 26 pressure vs. time waveforms are shown for the 
three in vitro setups described above and shown in Figure 18, Figure 20, and Figure 22, 
respectively.  In the first two setups (Figure 24and Figure 25), where the transducer 
experienced reflections from the air boundaries in close proximity to the active surface of 
the applicator there is a standing-wave-like interference pattern from the reflections at 
these boundaries.  These non-uniform oscillations in the pressure field were used as input 
to bubble dynamic models (Wrenn modified Rayleigh-Plesset [52]) to evaluate the level 
of the forces generated. 
55 
 
 
 
Figure 24: Pressure vs. time wave form of time-dependent model shown in Figure 18. 
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Figure 25: Pressure vs. time wave form of time-dependent model shown in Figure 20. 
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Figure 26: Pressure vs. time waveform of time-dependent model shown in Figure 22. 
 
4.4: Wrenn modified Rayleigh-Plesset bubble model 
This section provides the results from the MATLAB modeling of the acoustic behavior of 
bubbles in the field at 1-2 mm axial distance of the ultrasound transducer.  This modeling 
was done to quantify the forces that occur in the presence of microbubbles.  For more 
details on the model used please refer to [52].  Interestingly, these models also confirm 
the absence of cavitation due to the bubbles’ normalized radii never exceeding twice the 
resting radii (a cavitation predictor) for the experimental conditions considered.  As noted 
in [52], one method of predicting cavitation  is related to the bubble wall growth as 
predicted from the equation.  If the bubble wall expands in any given cycle to twice its 
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resting radius there is potential for cavitation to occur.  Below, a selected   number of 
graphs is displayed as representative examples, as there are nearly infinite parameter 
combinations for determining bubble behavior. The graphs are representative of bubbles 
having the maximum oscillatory potential – that is that the parameters were set so that no 
influence of bubble shell wall was used and they are in a water environment.  This was 
done so that the maximum possible stresses could be calculated, since with the addition 
of shell parameters the bubble wall oscillations are reduced. The bubble sizes ranged 
from 1µm to 150 µm and were selected as they represent the most likely range of 
possible sizes. The parameter values that were used in these models (unless otherwise 
mentioned) are listed in Appendix A and they represent what was determined to be an 
upper bound for the forces generated by the bubbles. 
 
 
Figure 27: Bubble radius vs. time curves for various bubble sizes calculated using the Wrenn modified Rayleigh-
Plesset equation with shell parameters  set to zero to determine the upper bound of forces caused by the bubbles.  
The pressure input to the calculation was the pressure versus time curve from Figure 24 (the transducer on top 
of the media) 
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Figure 28: Bubble radius vs. time curves for various bubble sizes calculated using the Wrenn modified Rayleigh-
Plesset equation with shell parameters set to zero to determine the upper bound of forces caused by the bubbles.  
The pressure input to the calculation was the pressure versus time curve from Figure 25 (the transducer on top 
of the media) 
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Figure 29: Bubble radius vs. time curves for various bubble sizes calculated using the Wrenn modified Rayleigh-
Plesset equation with shell parameters set to zero to determine the upper bound of forces caused by the bubbles.  
The pressure input to the calculation was the pressure versus time curve from Figure 29 (the transducer on top 
of the media). 
 
From the above figures, it can be seen that the choice of test fixture does indeed play a 
critical role in determining the acoustic propagation and field distribution that occurs.  
The three in vitro setups show that the same transducer operating at the same frequency 
and with the same acoustic output can produce different acoustic field distributions to 
occur at the within the media.  This further emphasizes the critical nature of choosing the 
appropriate test fixture to match the experimental conditions, however, as with all clinical 
applications, there is always a great variability among treatment groups and responses to 
treatment.   
When applying ultrasound using the applicator of Figure 2 the wound could be positioned 
in a number of different places on a patient’s body.  For the venous ulcers that were 
studied (Chapter 5 – Human studies) the wounds were located anywhere from the ankle 
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all the way up the calf. With many of the patients suffering from obesity the applied 
distribution of the ultrasound field within the treated tissue varied between patients.  This 
variation is more evident if the patient’s wound was near a bone (a reflector of acoustic 
energy) located at a depth of just a few (2-3) centimeters from the wound surface; in 
other patients no bone was present in the immediate wound vicinity. What can also be 
seen in the above radius-time graphs of bubble behavior (Figure 27, Figure 28, and 
Figure 29) is that maximal radial movements get larger, 1µm to approximately 50 µm, 
with larger, 5 µm to 100 µm radius, bubble sizes and also that they move at a higher 
(from millimeters to meters per second) velocity.  This is due to the fact that the 
resonance radius of the bubbles in a 20 kHz field is approximately 150 microns.  
The output of these models (bubble radial wall velocity and acceleration) was used to 
investigate the range of forces that could be potentially occurring at the tissue interfaces 
and within the tissue.  The acoustic forces that were investigated were radiation force and 
acoustic micro-streaming caused by “bubbles” in the sound field acting as secondary 
sources.  These values are calculated and shown in the final part of this Chapter (Section 
4.6).  
4.5: Kimmel-Krasovitski model 
As already discussed in the beginning of this section, a model for intra-membrane 
cavitation (stable and inertial) was created by Drs. Krasovitski and Kimmel at Technion-
Israel Institute of Technology. This model, discussed in detail in [53], will be briefly 
summarized here for convenience. For the purpose of the work described here, the model 
is helping with understanding the mechanisms of how ultrasound can induce bioeffects, 
below the cavitation threshold (≤100 mW/cm2).  Specifically, non-thermal, non-
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cavitational mechanisms that are also occurring with the ultrasound transducer described 
in this work.  The model assumes that there are no air-voids (cavitation nuclei) located 
outside of the cells, but that there is a “gap” between the lipid bilayers of a cell that can 
behave as gaseous nuclei (a small quantity of air - 5 nm in the model used here – per the 
original model specifications).  The original model from [50] was run and compared with 
experimental results that were found through exposure of ultrasound to live goldfish 
epidermis [53]. This supported the hypothesis that ultrasound induced bioeffects could be 
caused in the absence of air voids.   
The MATLAB code of this model was generously provided by KK-team and the model 
was run under the experimental conditions described here-in (55 kPa pressure amplitude 
– 20 kHz frequency). The relevant outputs of this analysis - membrane wall deviation and 
membrane tension are shown in Figure 30 and Figure 31, respectively.  The MATLAB 
code parameters used are shown in Appendix B.  From these figures, it is evident that 
there are in fact forces that could cause biological effects associated with the ultrasound 
conditions provided here.  Figure 30 shows cell wall radial fluctuations of almost 100 nm, 
and Figure 31 shows that the tension causes by these movements equate to around 200 
pN/m.  
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Figure 30: This graph shows the magnitude of the membrane separation (between the lipid bilayers) with 20 
kHz excitation frequency and 55 kPa pressure amplitude. 
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Figure 31: This graph shows the magnitude of the membrane tension with 20 kHz excitation frequency and 55 
kPa pressure amplitude. 
  
4.6: Microstreaming and radiation force calculations 
As mentioned in the introduction to this chapter, the mechanical forces generated by the 
ultrasound waves at 20 kHz with pressure amplitudes of 55 kPa were anticipated to be 
non-thermal and non-inertial cavitational. These conditions were also verified 
experimentally (see Chapter 5).  Hence, only mechanical forces generated by the 
ultrasound wave were examined.  Again, the investigation considered two different 
scenarios, one in the presence of air voids (gaseous pockets in the cells or bubbles on the 
surface in the coupling gel), and the other in the absence of air voids.   
Case I: Bubble-free medium:  
Evaluation of radiation force: 
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In the absence of air voids in the coupling medium and the skin, radiation force and shear 
stresses associated with displacements at boundaries act as primary mechanisms for 
bringing about biological effects.  As a first estimate the radiation force, generated by the 
applicator in Figure 2, that acts perpendicularly to the skin can be calculated as [5]:  
𝐹 [𝑁𝑒𝑤𝑡𝑜𝑛𝑠] = 𝑊 [𝑊𝑎𝑡𝑡𝑠]
𝑐 �𝑚𝑒𝑡𝑒𝑟𝑠
𝑠𝑠𝑒𝑐𝑜𝑛𝑑
�
=  0.1 𝑊𝑎𝑡𝑡𝑠𝑐𝑚2  ∗25𝑐𝑚2
1480 𝑚𝑒𝑡𝑒𝑟𝑠
𝑠𝑒𝑐𝑜𝑛𝑑
= 1.69 𝑚𝑁   
This takes into account the active area of the source in Figure 2 (2x2 array) 5 x 5cm = 25 
cm2), the speed of sound in water of 1480 m/s,  and 100 mW/cm2 (SPTP) intensity (the 
corresponding pressure amplitude is about 55kPa) produced.   
In a second approach to estimating the radiation force at any given spatial location in the 
acoustic field, a calculation proposed by Nyborg has been carried out [54]: 
�?⃗?�[𝑁𝑒𝑤𝑡𝑜𝑛𝑠] = 2 ∗  𝛼 �𝑑𝐵𝑚 � ∗ 𝐼 � 𝑊𝑐𝑚2�
𝑐 �𝑚𝑠 � =  2 ∗ 0.014 �
𝑑𝐵
𝑚 � ∗ 0.1 � 𝑊𝑐𝑚2� ∗ 25 𝑐𝑚21480 �𝑚𝑠 �  
≈ 48 µ𝑁 
This equation takes into account the same acoustic force and the acoustic impedance at 
the tissue interface.  The acoustic impedance was taken from [55]where it was calculated 
as 0.7 dB/m/MHz.  This value was then adjusted by incorporating the 20 kHz frequency 
to be 0.014 dB/m. 
Although this second value of radiation force is two orders of magnitude lower than the 
initial calculation as it incorporates the relatively low attenuation  (0.014 dB/m vs. 0.7 
dB/m) at the lower (20 kHz) frequency, it has still been shown in literature that this can 
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cause an effect.  Specifically,  the results discussed in  [56] may be relevant here; 
although the frequency used in [56] was much higher (1.5-3 MHz),  the results indicated 
that the lower the frequency the higher the displacement amplitude at a given frequency 
(as much as 10-fold from 3 MHz to 1.5 MHz).  It was shown in [56] that the radiation 
force was responsible for moving particles (phospholipid-shelled microbubbles, typical 
diameter 1-5 microns) , at 2.25 MHz, using pressure amplitude of 100 kPa, the estimated 
radiation force amplitude was calculated between 4.8 nN to 10.7 µN from 1-5 micron 
bubbles respectively.  Considering that the estimated 48 µN radiation force that is 
calculated above is almost, at minimum, five times greater than that shown in [56], it is 
plausible that low-frequency (~20 kHz) low-intensity (100mW/cm2 or 55 kPa) ultrasound 
will provide radiation force effects with a somewhat lower pressure amplitude (55kPa vs. 
100kPa [56]).   
Evaluation of stresses: 
When considering the non-thermal, non-inertial cavitation mechanisms of action between 
ultrasound and biological tissue it is appropriate to distinguish between the oscillatory 
and time independent (streaming associated) stresses.  The first order oscillatory stress 
can be estimated on the basis of Lamb's expression describing the behavior of fluid 
motion near a vibrating object (skin should move influenced by the radiation pressure at 
20 kHz) - [57-58].  The first order (oscillatory) stresses can be estimated [57] as a product 
of shear viscosity, angular insonification frequency and displacement amplitude divided 
by acoustic boundary layer thickness. Calculation of the boundary layer (equal to a 
radical of quotient of kinematic viscosity and angular frequency [6-7, 59-60]  was 
performed at 20 kHz assuming kinematic viscosity [m2/s] equal to 1•10-6 (it varies with 
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the temperature but this is a representative value used here to obtain an estimate) and 
yielded the thickness of 3.99 µm.  Within the acoustic boundary layer the velocity 
gradient is changing rapidly in the proximity of the boundary (here skin) and levels off at 
a distance of approximately 4 times the boundary layer thickness [7]. Consequently, in 
the immediate vicinity of the boundary there exists a relatively high shear stress equal to 
the product of the velocity gradient and viscosity.  Knowing the pressure amplitude or 
force, the displacement amplitude can be calculated by dividing force by angular 
frequency squared, i.e (2•π•20000)2 [Hz2], and using 0.001Pa•s as viscosity of the 
coupling medium (saline) yields a value of the shear stress of 2.59 Pa.  The 
corresponding velocity gradient of 1.1•105/s can be compared with the values reported in 
[61-63].  Therein, the cell membrane disruptions and fragmentation of small droplets 
were observed in vitro at velocity gradients as low as 0.5 •105/s, which is less than half of 
the value estimated above for the proposed insonification conditions.  
Case II- Bubble-containing medium:  
In this section, under the same assumed acoustic field conditions as those above, 
evaluations were carried out with the existence of bubbles.  These microbubbles will 
generate acoustic streaming (shown Figure 32) and the hypothesis was that the population 
of nuclei or bubbles, if they exist, either in the coupling medium or in the SC  [64] range 
in size from 0.1-10 micron. Such size bubbles will exhibit negligible displacement 
amplitude of their wall when exposed to 20kHz ultrasound field.  Therefore, in order to 
generate acoustic streaming with associated shear stresses sufficient to influence skin or 
cellular membrane properties, these bubbles must grow, ideally, to their resonance size 
(~150 microns radius at 20 kHz) through the rectified diffusion process [4, 65-66].  To 
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this end, Church simulations proved to be indispensable [67].  In this evaluation, it was 
assumed that 150 micron bubbles would be present and the shear stresses associated with 
acoustic streaming and pressure gradients were calculated using the thickness of the 
previously mentioned boundary layer (3.99 microns-Ref [6-7, 59, 68]) established in the 
vicinity of the cell membrane.   
 
Figure 32: Example of micro-streaming around a bubble at a lipid bilayer (cell-wall).  The lines and arrows 
represent the direction of the fluid flow. After [52]. 
 
Computer simulations and experimental verification of original Eller's data [66] 
presented by Church [67] at 26.6 kHz and 20kPa pressure-amplitude, comparable with 
the insonification conditions of this study, indicate that at 20 kHz resonance bubble sizes 
of 150 micron diameter would need about 8 minutes (relevant to the 15 minute exposure 
conditions), to grow from the assumed 10 micron radius size.  It was calculated that these 
10 micron bubbles should be able to grow at an approximate rate of up to 20 
microns/min. The rectified diffusion model (Equation 1) modified by Church [67] was 
used to quantify associated shear forces; Equation 1 lends itself to be solved in MATLAB 
using the ode45. The equation describes the average rate of change in the number of 
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moles of gas in a bubble of equilibrium radius Ro in a liquid of density ρ, and determines 
the radius to which the bubbles will grow depending on the insonification conditions.   
𝑑𝑅𝑜
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This equation allows examining rectified diffusion as a function of angular frequency 
(ω), diffusion rate (D), pressure-amplitude (PA), exposure time (t), Ci (dissolved gas 
concentration far from the bubble), Co (saturation concentration of dissolved gas in the 
liquid), surface tension (σ), initial radius (Ro), instantaneous pressure within the bubble 
(Pg), and the polytropic exponent (η), ranging from 1 to 1.4 [67].   
From the above equation and the Wrenn model discussed previously in the chapter  
(Section 4.4) shear stresses were calculated based upon the output of the applicator used 
at the previously explained exposure conditions.   The calculation of the shear stress was 
done using the following formula from [6]: 
𝑆 = 2𝜋𝑓𝐴𝑅0 � 𝜉𝑅0 �2 ∗ �𝜂𝜄𝛿 � 
Where                 𝛿 = [ 𝜂𝜄
𝜋𝜌𝜄𝑓𝐴
]12 
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In this equation S is the shear stress in Pascals, fA is the driving frequency (20 kHz), R0 is 
the resting radius of the bubble, ξ is the maximum displacement amplitude of the bubble 
determined from the nonlinear equation of bubble motion (Wrenn model), ηl is the 
coefficient of shear viscosity in water (0.001 Pa*sec), ρl is the liquid density(water), and 
δ is the acoustic boundary layer.  From this equation the following graph (Figure 33) was 
generated for bubble ranging from 5-150 µm . 
 
Figure 33: Maximum shear stress generated by an oscillating microbubble in the vicinity (<R0 distance) of the 
bubble wall.  The was determined by the largest amount of displacement generated for the various bubble sizes 
under a 20 kHz wave at 55 kPa pressure amplitude.  
 
(µm) 
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4.7: Summary of calculated forces and discussion 
In the following table, the range of forces that were calculated based upon the Wrenn 
(section 4.4) and KK (section 4.5) models as well as the relevant formulas discussed in 
section 4.6 of this chapter are given.  These forces represent a set of possible forces that 
occur using the applicator described herein operating at 20 kHz with a pressure amplitude 
of 55 kPa (corresponding to 100 mW/cm2 ISPTP).  
 
Force Calculated Possible biological end-point 
Bubble-free 
medium 
Radiation Force 50µN-1.6mN Moving of phospholipid-shelled microbubbles [56] 
Tension (KK 
Model) ~200 pN/m 
Open mechano-transduction 
channels in steriocilia 
(100pN) [69] 
Bubble Radii 
(1-20 µm)  
Shear-Stress 
(Wrenn model) 0.1-100 Pa 
Fibroblast growth factor 
release (1.6 Pa) [70], Nitrous 
oxide release (2.6 Pa) [71] 
Bubble Radii 
(20-100 µm)  
Shear-Stress 
(Wrenn model) 100 – 1000 Pa Hemolysis (150 Pa) [72] 
Bubble Radii 
(100-150 
µm)  
Shear-Stress 
(Wrenn model) 1000 – 1700 Pa 
Angiogenic responses (1-10 
kPa) [73]  
 
It is necessary to briefly discuss the physiological relevant forces that naturally occur in 
the human body in order to infer the clinical implications of using the ultrasound 
applicator described in this work.  Shear stresses naturally occur in the human body as 
blood flows through the veins and arteries throughout the body.  Typically these stresses 
are in the range of 0.1-20 Pascals in a healthy human vein or artery, 20-50 Pascals in a 
stenotic artery, and as much as 1000 Pascals in an artificial hearts and valves [74]. Shear 
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stress is also known to induce in vitro effects such as hemolysis (150 Pa) [72], fibroblast 
growth factor release (1.6 Pa) [70], nitrous oxide release (2.6 Pa) [71], and angiogenic 
responses (1-10 kPa) [73].  As can be seen in the table above shear stresses generated by 
the applicator investigated here produce biologically relevant stimuli.  Furthermore these 
activities are activated by a large range of stresses ranging several orders of magnitude 
(1Pa to 10,000 Pa).  It should be noted that the large shear stress values (on the order of 
kPa) are generated at the tissue interface by oscillating bubbles at the tissue interface as 
in [73]. 
In the next Chapter experimental validation of the simulated ultrasound applicator is 
presented with in vitro and in vivo experiments.  
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Chapter 5: Aim 3: Experimental validation of ultrasound efficacy in accelerated 
wound healing  
5.1: Introduction: Experimental validation of ultrasound mechanism (presence of 
inertial cavitation), efficacy in accelerated wound healing using human (in vivo) and 
effect on fibroblast cell culture (in vitro) experiments 
This aim was to experimentally validate the claims made throughout this thesis.  This 
included determining the efficacy of the ultrasound applicators’ effects on both in vitro 
cells and living human patients while also ensuring that the applicator was “safe” by 
ruling out the presence of inertial cavitation.  Initially, cavitation experiments were 
performed to determine if the applicator, working at the desired 20 kHz frequency with 
an output of 55 kPa (100mW/cm2 ISPTP), was capable of producing inertial cavitation.  
These tests (discussed in details below) were performed with both a physical and a 
chemical dosimeter and determined that there were in fact no inertial cavitation events 
detected.  In conjunction with the cavitational testing, temperature monitoring of the 
media and the applicators was also performed and it was determined that at the driving 
conditions described herein there was no self-heating of the applicator nor temperature 
elevation over 0.5 degrees Celsius in the cellular media.  After ruling out both thermal 
and non-inertial cavitation it was decided that the device was safe for prolonged use on 
human subjects.  This then led to data being collected in vivo with human patients (after 
appropriate IRB approval) and in vitro with fibroblast cells.  These data sets are presented 
after the cavitation verification section. 
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5.2: Experimental identification of the presence of inertial cavitation:  
To determine the presence or absence of inertial and stable cavitation three independent 
techniques were used: aluminum foil pitting [75],  broad band spectrum analysis [76-77], 
and Terephthalic Acid (TA) fluorescence [78-79]. The expected results were obtained (no 
inertial cavitation was detected), in all of experiments, yet each method was verified 
using devices known to create cavitation (discussed in detail below).  Examples of 
Aluminum foil pitting and acoustic spectrums created with inertial cavitation are shown 
in Figure 35.  The examination of aluminum foil pits and the conversion of Terephthalic 
Acid (TA) to Hydroxyl-Terephthalic Acid (HTA – a fluorescing molecule) (see Figure 
35) are indicative of the existence of inertial cavitation only, whereas the acoustic 
spectrum measurement (FFT of the time domain signal received by the hydrophone) 
provides information on both stable and inertial cavitation [76-77].  Also, Tezel and 
Mitragotri [43] used the aluminum foil pitting technique at intensity levels from 0.7- 3.6 
W/cm2 for 10 seconds and ascribed the number of pits as an approximate indicator of the 
number of cavitation events that took place in their experiments. Their results were 
considered when testing the applicator of Figure 2The presence of free radicals (OH-), as 
demonstrated by the conversion of terephthalic acid to hydroxyl-terephthalic acid which 
fluoresces, was also used as a method of detecting inertial cavitation [78-79].  
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Figure 34: Terephthalic acid (non-fluorescing molecule) conversion to hydroxyl-terephthalic acid which is used 
as a fluorescent indicator for cavitation  
 
Figure 35: Left: Example of aluminum foil pitting for qualitative detection of inertial cavitation - A 20µm thick 
foil membrane was exposed to shockwaves generated by a lithotripter in an independent test performed by Dr. 
Peter A. Lewin. Right: A single shockwave (time domain). 
 
Cavitation Detection Results: Both chemical and physical inertial cavitation detection 
methods were employed with the portable applicator that has been previously described. 
Tests were performed after positive controls were used to ensure the accuracy of the test 
fixtures.  The test fixtures were developed in house for both the physical and the chemical 
testing.   
The chemical dosimetery test fixture consisted of a pipette filled with a solution of 
Terephthalic Acid at a concentration of 5 mM.  This sample volume was then exposed to 
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ultrasound using a sonicator (Misonix XL-2020) that was known to produce inertial 
cavitation.  A cavitation curve (Figure 36) was then developed to determine the threshold 
for detection of cavitation as well as the “amount” of cavitation.  This experiment was 
useful because even small amounts of cavitation can be detected by increasing the time of 
application.  Therefore, to verify the absence of cavitation the ultrasound applicator was 
used for a duration of 60 minutes on the sample volume.  No inertial cavitation was 
detected using this method. 
 
The physical dosimetry test fixture compromised of an acrylic ring that fit snuggly into 
an outer cut circle.  This was done so that aluminum foil could be pulled taut like a 
membrane – in this way the “pitting” could be visually discernible (Figure 37).  The test 
fixture was then subjected at a distance of 3 mm (emulating the clinical scenario) to an 
ultrasound field generated by sonicator (Misonix XL-2020) set to its lowest power setting 
with 10% duty cycle. Even at this lowest setting visual evidence of the presence of 
inertial cavitation was observed.  After determining the efficacy (cavitation was 
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Figure 36: An experimentally derived calibration curve of various Hydroxyl-Terephthalic Acid (HTA) concentrations. 
These curves can be compared to an ultrasound exposed Terephthalic Acid (TA) solution in order to make a 
quantitative assessment on the amount of inertial cavitation that has occurred. 
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detectable) of the test fixture the ultrasound applicator was used for 60 minutes with the 
applicator parallel - ultrasound waves traveling directly at – the foil at a distance of 3 mm 
of the foil (to match clinical scenario).  As already noted, no inertial cavitation was 
detected with this method either. 
 
Figure 37: Example of aluminum foil pitting caused by inertial cavitation using sonicator (Misonix XL-2020) set 
to 10% power at 3 mm distance from the tip of the horn in the physical dosimeter test fixture. 
 
It should also be noted that although no test fixture was specifically developed for the 
acoustic dosimetry method, a Reson 4038 hydrophone was regularly used to calibrate the 
applicator.  This same hydrophone was used to identify the presence of cavitation during 
all above described calibration procedures.   
After verifying the claims that no inertial cavitation was occurring in vitro and in vivo 
experiments were performed, including the fibroblast experiments discussed next. 
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5.3: In vitro – Fibroblast Experiments 
To a large extent, the text in this section is from the peer-reviewed, published, and  co-
authored paper, “Low-frequency (<100 kHz), low-intensity (< 100 mW/cm2) ultrasound 
to treat venous ulcers: A human study and in vitro experiments.”  
Fibroblast preparation and ultrasound exposure 
As already mentioned, in vitro verification of the proposed applicators ability to stimulate 
an advantageous biological response was conducted by examining the effect of 
ultrasound exposure on fibroblast cells.  The fibroblasts, chosen due to their documented 
role in wound healing [1-2], were seeded in sterile 6-well transparent plates at 1 X 104 in 
2 mls of Dulbecco's modified Eagle’s medium (Life Technologies, Carlsbad, CA) with 
10% bovine serum.  The 6-well plates were then wrapped in acoustically transparent 
plastic wrap in order to maintain a sterile environment.  The cells were cultured between 
18 and 20 hours, to allow cells to adhere to the wells and begin cell growth cycle, in an 
incubator at 37° C, with 5% CO2 and 80-90% humidity.  After this initial growth period, 
cells were removed from the incubator for exposure with the ultrasound, which occurred 
at room temperature.   
For the in vitro experiments, all cells were exposed to 20 kHz ultrasound for 15 minutes 
(chosen based on results of the in vivo treatment).  The geometry of the exposure 
container (see Figure 38) was intentionally chosen to closely mimic the in vivo exposure 
conditions.  Similarly, the biological assays chosen were carefully selected to determine 
cellular metabolism (alamarBlue) and proliferation (BrDU). 
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When the cells from both experiments were ready for insonification, the ultrasound 
applicator was placed below the 6-well plate to transfer the ultrasound energy in a non-
contact, sterile manner, shown in Figure 38.  The acoustic output of the applicators was 
adjusted to account for any attenuation experienced due to the relatively thin (1.3 mm or 
0.017 λ at 20 kHz) plastic bottom of the well plate.  Treatment and control (sham) 
exposures were performed simultaneously in separate well plates, to minimize any 
potential variability between samples, while eliminating concerns of sham group 
exposure to any potential reflected ultrasound.  Due to the relatively long (75 mm) 
wavelengths of 20 kHz ultrasound, the pressure gradient across the sample (~2 mm) at 
any time point was negligible.  With this, the experimental setup was not subject to nodes 
or anti-node formation within the medium and therefore was not a concern because even 
in the worst case scenario, cells would be exposed to a maximum of 200 mW/cm2 ISPTP, 
which, under the experimental conditions used here, complies with FDA safety 
guidelines [20].  After exposure, cells were cultured for an additional 24 hours prior to 
the cellular metabolism and proliferation assays.   
 
Figure 38: In vitro experimental setup showing ultrasound applicator and sterile plate containing fibroblasts in a 
growth media.  Ultrasound applicators produced 20 kHz ultrasound with a corresponding wavelength of ~75mm 
[80].   
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In vitro results 
The results of the cellular metabolism assay comparing the various treatment groups to 
the control are shown below in Figure 39.  A two-factor ANOVA analysis (used because 
there were two variables being examined between three groups) determined that whereas 
there was no statistical difference between the applied pulse repetition frequencies 
(p>0.05), the intensity was statistically significant (p=0.02).  A post-hoc Tukey test (a 
typically used method to evaluate which means are statistically different from one 
another in a multiple group analysis) confirmed that the 100 mW/cm2 group statistically 
outperformed both the 50 mW/cm2 group (p<0.05) and the 200 mW/cm2 group (p<0.04).   
 
Figure 39: Average fibroblast cells growth, for cells exposed to ultrasound with respect to cells that were not 
exposed to ultrasound (incubator control/sham).  The groups are separated into the three intensity levels 
(50,100, and 200 mW/cm2 SPTP), and within each level, the dark gray bar represents the 1 Hz PRF, the medium 
gray represents 10 Hz PRF, and the light gray represents 20 Hz PRF.  Bars indicate standard error with six 
repetitions of each condition [80].  *p<0.05 
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The results of the in vitro experiment, measuring cellular proliferation, also indicated that 
the ultrasound application had a significant effect. The cells receiving ultrasound 
treatment (20 kHz for 15 minutes at 100 mW/cm2) had an average of 35% increased 
cellular proliferation when compared to the control cells, a statistically significant 
increase (p<0.01). 
5.4: In vivo – Human studies 
This section consists of three independently performed studies that were run 
consecutively for treatment of first, chronic venous ulcers, and then, chronic diabetic 
ulcers.  Initially a preliminary study was performed to determine whether ultrasound at 
the desired acoustic output levels discussed here had an effect and if so, what parameters 
were best suited for testing.  The follow up venous ulcer study took the acoustic 
parameters that were most beneficial in the pilot study and applied it to more venous 
ulcer patients to improve statistical significance and power of the study.  The final study 
presented in this Chapter summarizes the outcome of another pilot study for diabetic 
patients using the exact same acoustic parameters.  This was done to see whether the 
ultrasound applicator was capable of producing a beneficial effect on chronic wounds 
other than venous ulcers, which have much different etiologies, effectively increasing the 
target treatment population. 
Pilot study to hone in on optimal frequency and duration for venous ulcer patients: 
Much of following text in this section was taken from the co-authored paper “Low-
frequency (< 100 kHz), low-intensity (< 100 mW/cm2) ultrasound to treat venous ulcers: 
A human study and in vitro experiments” [80]. 
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Patient selection and application 
To verify the efficacy of the applicator design, in vivo experiments were carried out with 
IRB approval on twenty patients with chronic venous stasis ulcers that were recruited 
from Drexel University Wound Healing Center.  Upon enrollment, subjects were 
randomly assigned to one of four experimental groups: 15 minutes of 20 kHz ultrasound, 
45 minutes of 20 kHz ultrasound, 15 minutes of 100 kHz ultrasound, or 15 minutes of 
sham (no treatment).  All active treatments were at 100 mW/cm2 ISPTP.  Due to the non-
normality of distribution of wound initial sizes and ages of the wounds, the logarithmic 
transforms of the areas and ages were calculated to facilitate comparisons and later 
statistical analysis.  
It should be noted that standard wound care treatment as determined by the physician was 
performed for all enrolled subjects, including weekly or bi-weekly debridement, 
compression therapy, edema control, and any prescribed topical therapies.  During each 
treatment session, the ultrasound applicator, shown in Figure 2, was wrapped in an 
acoustically transparent sterile wound dressing and coated with sterile ultrasound gel.  
The applicator was then placed directly on the wound and affixed using surgical tape.  
Once secured in place, the applicator was then turned on for the amount of time dictated 
by the patient’s experimental group.  Following insonification, the applicator was 
removed and a photograph for wound size determination was taken.  
Venous ulcer pilot study results 
Of the total 20 patients who enrolled in the study, 10 subjects healed and 10 did not heal 
during the four treatments of the study.  Eight of the 15 treated ulcers healed in the four 
treatment time frame in comparison to two of the five in the sham group.  One particular 
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group, namely those patients receiving 20 kHz for 15 minute, experienced complete 
healing in 100% (n=5) of subjects by the 4th treatment.  Representative photos of a non-
healing and healing patient from the sham and 20 kHz, 15-minute treatment group are 
shown in Figure 40. 
 
Figure 40: Representative wound photos from a non-healing ulcer in the sham group (left) and a healing ulcer in 
the 20 kHz, 15 minute treatment group (right).  Images feature line tracing the wound perimeter as part of the 
wound sizing software [80].  
 
As already noted, the progress of healing was assessed through wound size reduction.  
All wound areas were normalized to the initial size.  This was done to facilitate intra-
wound comparisons due to the variance in the initial wound sizes (0.7 to 22 cm2).  The 
normalized size data for all visits were then plotted over time for each individual. The 
best fit of the normalized wound size data was calculated using a first degree polynomial 
(y = mx + b), where y was the normalized data, x was time in weeks, b was the 
normalized initial wound size from the line of best fit, and m the slope of the line. The 
calculated slope (m) represented the percent wound size change per week, which was 
used as a primary endpoint to analyze the effect of the ultrasound treatment.  
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Figure 41: Comparison of percent change in wound size by experimental group as measured using manually 
traced images which were analyzed using computer software designed by this lab group.  Bars indicate standard 
error [80]. 
 
The results presented in Figure 41 indicate that the average rate of closure for the 20 kHz, 
15 minute treatment group was statistically (p<0.03) improved, resulting in faster 
reduction in area per week compared to the sham group, as determined by a one-tailed 
student's t-test.  Although the mean rate of change in wound size was negative (indicating 
healing) in the other two treatment groups (20 kHz, 45 minutes and 100 kHz, 15 
minutes), the differences were not statistically significant from those obtained with sham, 
which had an average increase in wound size of 3% per week (n=5). 
In addition, it should be noted that the average initial wound size for the five human 
subjects in the 20 kHz, 15min treatment group was nearly identical to the average non-
healing ulcer in the sham group (4.8 cm2 vs. 4.7 cm2) , showing that wounds of the same 
size, when treated with ultrasound did heal, whereas those not-treated did not heal.  
Furthermore, the five healing wounds of the 20 kHz, 15min treatment group had an initial 
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size that was nearly twice as large as the average healing ulcer for the overall study (4.8 
cm2 vs. 2.7 cm2), highlighting the efficacy of this particular treatment.  
Follow up venous ulcer studies to determine efficacy: 
A portion of the following discussion was taken from the co-authored paper “20 kHz, 
Ultrasound Assisted Treatment of Chronic Wounds with Concurrent Optic Monitoring: A 
Human Study” [81]. 
Patient selection and treatment 
For all clinical studies discussed here, in addition to ultrasound treatment, the patients 
continued to have standard wound care treatment as determined by the physician.  This 
treatment included weekly or every other week debridement, compression therapy as 
edema control (if applicable), and any prescribed topical therapies.  All of the clinical 
studies’ protocols were reviewed and approved by the Drexel University College of 
Medicine Institutional Review Board (IRB) and patient recruitments were done at the 
Drexel University Wound Healing Center, Philadelphia, PA.     
 During each treatment session, topical anesthetic (typically Lidocaine) was applied to the 
wounds before ultrasound insonification.  The ultrasound applicator (Figure 2), wrapped 
in an acoustically transparent sterile wound dressing (Tegaderm®) and coated with sterile 
ultrasound gel (Aquasonic® 100).  The applicator was then placed directly on the wound, 
affixed using surgical tape, and turned on for 15 minutes.  Following insonification, the 
applicator was removed and a photograph was taken for use during wound size 
determination.  Each picture had a one inch marker in the frame, which facilitated 
calculation of the wound area.  The wound boundaries were traced by hand and the 
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surface area was calculated using a previously described program [82] using MATLAB® 
software (MathWorks Inc., Natick, MA). 
Ultrasound Therapy Results 
The rate of healing per week was calculated by looking at the wound area reduction over 
time.  The wound size data of each patient was normalized to their respective initial 
wound size in order to allow a relative comparison between patients. Patient data was 
categorized into groups based on treatment type and healing outcome.  Healing and non-
healing wounds were initially analyzed, followed by treated and non-treated wounds.   
The initial wound sizes were found to be normally distributed, and were thus hypothesis 
testing was conducted using a Student’s T-test.  In addition, the p-value of the wound size 
comparison was 0.566, which indicated a failure to reject the null hypothesis (ho ≥ 0.05) 
and designated that the two groups had no significant difference in size. The t-test 
comparing the treatment and non-treatment group healing rate provided a p-value of 
0.0023 (p < 0.05).  This indicated a statistical significance between groups in rate of 
healing.  This supports the findings in Figure 42, which show that the treatment group 
had a mean rate of healing which was statistically different from the non-treatment group. 
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Figure 42: n=25 patients, 13 treated, 12 sham treated, normalized scatter plotted with slope as percentage 
reduction.  Standard error bars (+/- 7.2% treated and +/- 4.7% sham treated).  A t-test was used and found 
significant difference between the means (p<0.05) with p=0.002. 
 
After performing the analysis, to determine the difference between treated and sham-
treated groups the data was further categorized into healing and non-healing patients.  
This was done to facilitate further comparisons between the groups, since not every 
patient responds the same way to treatment.  To do this average rate of wound size 
change was calculated for each patient and patients that had a negative (reduced) percent 
change were considered healing and positive (growth) was considered not-healing.  
Figure 43 and Figure 44 show pie charts that clearly illustrates that a higher percentage of 
patients were healing with the treatment (71%) than without the treatment (55%).  This 
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indicates the possibility that more patients are capable of healing with active ultrasound 
treatment in addition to standard of care as opposed to standard of care alone.   
 
Figure 43: Treated venous ulcer patients, healing versus not-healing. 
 
Figure 44: Sham treated venous ulcer patients, healing versus not-healing. 
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Furthermore, Figure 45 and Figure 46 show the average healing rate percentages per 
week for both healing and non-healing patients, respectively.  These groups were also 
tested for statistical significance using a t-test and it was found that both exhibited p-
values <0.10, which indicates that although the means of the two populations are 
different, the results may not be significant.  For the healing group p=0.07 and for the not 
healing group p=0.09.  It would be necessary to increase the number of patients treated to 
decrease the p-value (making the results of the test more statistical significant). 
As observed in Figure 45, within the patient group showing signs of healing, ultrasound 
treated patients had a healing rate almost four times that of the non-treated patients.  For 
the patients whose wounds were not healing (Figure 46), the growth (increasing of wound 
size) rate per week was almost ten times lower for the treated patients than that of the 
non-treated group.  This shows that within the non-healing group, even patients who 
appeared not to be responding to treatment had a much slower (~10x less) increase in 
wound size than the untreated wounds.  It is plausible that the applicator device has a 
positive effect even in the case of non-responding wounds as it is actively slowing the 
wound area development. 
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Figure 45: Of the healing patients, the rate of wound closure per week for the ultrasound treated and sham 
treated groups.  Standard error bars, sham treated +/- 1.7%, ultrasound treated +/- 9.4% sham treated.   
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Figure 46: Of the not-healing patients, the rate of wound closure per week for the ultrasound treated and sham 
treated groups.  Standard error bars, sham-treated +/- 8.3%, ultrasound-treated +/- 0.3%. 
 
 
Diabetic pilot study: 
There were 10 patients in the diabetic ulcer group at the beginning of the study. One 
patient dropped out of the study after a heart attack and medical complications, and 
another patient dropped out of the study after two applications for unknown reasons.  Of 
the remaining 8 patients, all patients demonstrated a healing trend.  The t-test concluded 
that the average rate of closure was statistically significant (p<0.5) with a p-value of 0.01.  
The weeks to closure was also found to be statistically significant (p<0.05) with a p-value 
of 0.03 
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The wound sizes of the diabetic wounds were also normalized for comparison, and the 
percentage change in wound size per week was computed. If a patient missed a day, or 
more, the projected wound size was included in order to properly normalize the data.  
Figure 47 below shows the average percentage wound change per week for diabetic 
patients.  The treated group’s ulcers healed at an average rate of -32.0% per week, while 
the non-treatment group healed -5.8% per week. 
 
Figure 47: Percent Change in Wound Size in Diabetic Ulcers per Week.  The treated diabetic ulcers closed as 
much as five times faster than the non-treated diabetic ulcers.  Standard error, ultrasound treated +/- 2.8%, 
non-treated +/-1.6%. 
 
The average weeks to closure of the treated patients was 5.7, while the average weeks to 
closure for non-treated patients was 12.0 (shown in Figure 48 below).  This indicates that 
treated wounds closed approximately twice as fast as the non-treated wounds and saved 
an average of 6 weeks of treatment.     
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Figure 48: Average weeks to full closure for diabetic ulcers. Standard error, ultrasound treated +/- 0.5 days, 
sham-treated +/-1.5 days. 
 
In vivo Conclusions 
The results presented are encouraging as they indicate that the ultrasound applicator 
operating at the safe energy level (100 mW/cm2) corresponding to peak-to-peak pressure 
amplitudes of 55kPa (ruling out the presence of inertial cavitation and thermal effects) is 
capable of accelerating healing of both chronic venous and chronic diabetic ulcers.  Also 
encouraging was a simple patients’ survey, where during the treatment the patients were 
asked how they felt about the device.  These results indicated that all the patients found 
the device user-friendly and almost all (90%) of the patients reported feeling only a slight 
5.7 
12.0 
Average Weeks to Full Closure  
(Diabetic Ulcers) 
Treated Sham Treated 
94 
 
tingle with no pain (in fact, 100% reported feeling no pain) associated with the operation 
of the device during the treatments, whereas the remaining 10% reported no sensation at 
all.  However, although somewhat puzzling, 70% of non-treatment patients also reported 
feeling a tingling sensation, while being treated with sham device.  It is conceivable that 
this was due to the placebo effect or that the sensation of the device placed on the wound 
created a tingling perception.  The results found in the in vivo studies were very 
promising and more studies are being designed for further clinical studies involving more 
patients from the groups already being studied as well as expanding the potential chronic 
wound healing market to include pressure ulcers.  In addition to accelerated chronic 
wound healing the device is also explored for use in transdermal drug delivery 
applications.  A pilot study exploring this potential application of the ultrasound 
applicator is described in the next chapter.    
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Chapter 6: Transdermal drug delivery pilot study 
Parts of the following chapter use verbatim phrasing taken from the pre-published version 
of the co-authored manuscript titled “Enhanced therapeutic anti-inflammatory effect of 
betamethasone upon topical administration with low frequency, low intensity (20 kHz, 
100 mW/cm2) ultrasound exposure on carrageenan-induced arthritis in mice model.”  
This manuscript was accepted for publication in the journal “Ultrasound in Medicine & 
Biology,” in April 2015 [83].  
6.1: Introduction 
The purpose of this study was to investigate whether low frequency, low intensity (LFLI 
is defined here as: 20 kHz, <100 mW/cm2, spatial-peak, temporal-peak intensity) 
ultrasound (US), delivered by a light-weight (<100g), tether-free, fully wearable, battery 
powered applicator is capable of providing a therapeutic effect in a mouse model of 
inflammatory arthritis.  
The primary motivation for this work was to explore the possibility of syringe-free 
delivery of topically applied drug using the aforementioned ultrasound applicator at 20 
kHz 100 mW/cm2 (non- thermal and non-cavitational) levels of ultrasound.  Such 
noninvasive delivery is of importance for both societal and economic reasons, because of 
the adverse reaction or physical inability to administer the drugs orally and reduction in 
cost of treatment associated with the delivery tools (no syringes needed and no need for 
controlled disposal of the syringes).  Non-invasive delivery is also of interest because oral 
intake of a variety of drugs might be impeded due to side-effects such as decreased white 
blood cell counts, increased risk of infections, fatigue, oral ulcers, hair loss, nausea, and 
diarrhea, and liver toxicity.  The pre-clinical evaluation was performed using a mouse 
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model of rheumatoid arthritis (RA).  RA was chosen because it is often encountered 
in children and juveniles.  To minimize the side effects pediatric rheumatology treatment 
usually requires drugs to be injected, which is painful.  Also, many children develop 
such psychological aversion to these injections that they vomit prior to drug 
administration.  Moreover, invasiveness of delivery increases health care costs and 
reduces patient compliance.  In the following, the harmful effects of RA are highlighted. 
Rheumatoid arthritis (RA) is a chronic, debilitating inflammatory, musculoskeletal 
disease that affects 0.5-1.0% of the adult population in Western countries, with total 
treatment costs approaching $80 billion annually [84-85].  Its pediatric sibling, Juvenile 
Idiopathic Arthritis (JIA) affects 0.01-0.4% of children [86].  The joint destruction and 
progressive functional disability associated with uncontrolled inflammation impact ability 
to work, attend school, overall quality of life, and mortality [87-88].   
Systemic Corticosteroids (CS) most often control disease in inflammatory arthritis, RA 
and JIA.  However, if given for a prolonged period, they result in significant morbidities, 
including glaucoma, cataracts, weight gain, hypertension, diabetes, and bone fragility 
[89-90]. Therefore, alternate systemic agents, are added to spare exposure to steroids.  
These include: hydroxychloroquine, disease modifying agents (e.g. methotrexate), non-
steroidal anti-inflammatory agents, and biologic agents [91-93].  These non-steroidal 
agents have potential side effects including, cytopenias (reduced blood count), increased 
risk of infection, and pain (from subcutaneous injections).  While biologic agents may be 
helpful in recalcitrant disease, they typically cost 10 to 100 times more than older 
therapies, and there has been a global concern regarding their impact on healthcare 
budgets  [84].  These concerns have prompted interest in research and development of 
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novel, economically acceptable, safe delivery methods of existing anti-inflammatory 
drugs, including CS, to patients with inflammatory arthritis.  The primary goal of these 
research efforts are to minimize the side effects of the drugs taken systemically or 
injected intra-articularly while maximizing their potency in alleviating arthritis. 
Intra-articular CS injections (IACI) are frequently used in the management of patients 
with inflammatory arthritis.  They are preferred over systemic agents to treat mono-
articular/oligoarticular arthritis [94].  Even in polyarticular disease, the addition of IACI 
to systemic combination therapy helps achieve “tight control” of RA in a manner that 
may obviate the need for biologics [91, 95-96]).  While studies have demonstrated, at 
least in children, that triamcinolone hexacetonide (with the lowest solubility) is the most 
effective [97], clinical effect has been demonstrated with methylprednisolone, 
betamethasone, triamcinolone acetonide, and triamcinolone hexacetonide IACI [98]. 
IACI have rapid onset, often within the week.  Following IACI, arthritis is controlled in 
63-82% of children at 6 months , 45%-50% at 12 months in JIA [99-100]. However, 
IACI are acutely painful and while not in adults, in children they often result in the need 
for sedation.  Moreover, they can result in osteoporosis [101], skin hypopigmentation, 
subcutaneous atrophy, or rarely introduce infection into the joint [102-103].  Although 
intra-articular administration of CS derivatives can result in rapid onset of a durable anti-
inflammatory response that may limit or obviate exposure to systemic medications [91, 
95-96, 104], alternative effective but non-invasive ways to deliver local CS are needed.  
The fully wearable, battery operated ultrasound applicator described here alleviates these 
issues.  In particular, as already noted, it might provide a painless route of treatment, 
while minimizing side effects.  It also offers a potential for home treatment without the 
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need to visit the physician’s office.  This, in turn, will potentially enhance the patient’s 
quality of life and by eliminating the need for transportation to the hospital, further 
reducing the cost of treatment.  
The research in ultrasound assisted drug delivery has gained increasing attention over the 
past two decades.  While there is bevy of publications on the topic, here, for brevity and 
convenience, only one extensive and systematic review describing the current knowledge 
and state-of-the-art of US assisted drug delivery is highlighted.  This recent, well-
documented (with 181 references) survey was published by the team of researchers from 
Ben Gurion University, Beersheba, Israel  [105].  The information provided therein [105] 
should be helpful in facilitating an insight into the encouraging outcome of the in vivo 
animal study described in the following. 
In the Materials and methods section, the ultrasound applicator used in this study is 
presented along with all relevant exposure parameters. In addition, the conditions of the 
in vivo mice experiments are described.  Next, the results indicating the potential of the 
LFLI ultrasound assisted transdermal drug delivery are outlined and followed by the 
discussion and conclusions.  
6.2: Materials and methods 
Prior to description of the applicator used in the experiments described in the following, 
it might be useful to elucidate the choice of the US field parameters employed in this 
study.  
The initial literature review suggested that US at frequencies in the tens of kHz range 
might be more effective for noninvasive, transdermal drug delivery in comparison to the 
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diagnostic imaging 1-3 MHz interval.  This notion was also supported by the outcome of 
our  independent study [106]  in which 20 kHz US caused more liposome membrane 
disruption than 1 MHz and 1.6 MHz ultrasound.  These findings were further supported 
by Sundaram, Mellein and Mitragotri [107]; they reported that exposure to 20-100 kHz 
range US caused increased fibroblast membrane permeability providing a defined 
biological effect which may be relevant to the therapeutic effects of US.    
The operational parameters of the ultrasound applicator  [108] used in the current 
experiments is described below.  
Ultrasound applicator  
The applicator [80, 108] operated at 20 kHz and delivered 50% duty cycle, 55 kPa peak-
to-peak pressure amplitude corresponding to 100 mW/cm2 spatial-peak, temporal–peak, 
intensity (ISPTP). To optimize battery lifetime (between re-charging) pulse repetition 
frequency was chosen to be 25 Hz [80]. An early prototype of an ultrasound applicator 
used in the experiments described in the next section is shown in Figure 49, along with the 
compact box containing electronic circuitary including custom-built tone burst generator 
powered by rechargeable lithium-ion batteries. A detailed description of construction, 
principle of operation and characteristics of the device was given in [108]. The 
lightweight (< 25 g), small foot print (approximately 20 mm x 20 mm x 8 mm) applicator 
was designed to be used as a tether-free, fully portable tool. As noted earlier, the 
applicator was driven by a 20 kHz tone-burst sinusoidal excitation waveform with a 20 
ms pulse duration delivered at a PRF (pulse repetition frequency) of 25 Hz. The 
applicator was activated using a custom designed battery-operated driving unit. The heart 
of the applicator is a piezoelectric ceramic disk (PZT 4), sandwiched between the metal 
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caps, and the whole flexural element is 2-3 mm in height. Typically, the thickness of the 
capacitive piezoelectric element is inversely proportional to the frequency, and where a 1 
MHz (typical therapeutic frequency range) element is about 2 mm in thickness, a 20 kHz 
element would need to be 10 cm thick. Fundamental thickness operation of such an 
element would require excitation on the order of 100's of volts, adding bulk and removing 
any chance of being a portable design.  The design was implemented as a mechanical 
displacement amplifier, which, much like a gearbox can scale movement up or down, 
translates 2 MHz US waves into 20 kHz output at the desired pressure amplitude of 55 
kPa (this amplitude corresponds to spatial-peak, temporal-peak intensity level of 100 
mW/cm2, ISPTP) with only 12-15 volts excitation. Without this technique, a large (and 
heavy, typically well above 10 kg) power amplifier would be needed to drive the highly 
capacitive piezoelectric ceramic load. 
 
Figure 49: Single element 20 kHz ultrasound applicator used in the transdermal study along with the compact box 
containing electronic circuitry for exposure control and application on mice limbs.  
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The acoustic output of the applicator was measured in 22 °C de-ionized water, using a 
calibrated hollow cylinder hydrophone, with a diameter of 2 mm [109].The two-
dimensional (2D) pressure amplitude map of the applicator’s acoustic output distribution 
is shown in Figure 50. The pressure measurements were performed at a distance of 2.5 
mm away from the transmitting surface of the transducer (to mimic a clinical 
application).  For the sake of the discussion it is appropriate to underscore that the 
applicator’s pressure amplitude was set to 55 kPa (corresponding to 100 mW/cm2 ISPTP ) 
to – intentionally – rule out inertial cavitation, a phenomenon where gas bubbles violently 
implode and may cause tissue damage [3].  This pressure amplitude is also considered 
safe even at prolonged (>250 minutes) exposure time, according to the 2008 Statement on 
Mammalian In-vivo Ultrasonic Biological Effects from the American Institute of 
Ultrasound in Medicine [20].  
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Figure 50: Two-dimensional representation of the pressure field distribution on the paw, measured at an axial 
distance of 2.5 mm from a single element applicator.  Two-dimensional beam plot showing uniform ultrasound 
field distribution of the flexural ultrasound applicator at the axial distance of 2.5 mm. Normalized two-
dimensional surface pressure amplitude distribution measured at the axial distance of z = 2.5 mm of the 
applicator having characteristics shown in Figure 49.  Y-axis: left to right direction, X-axis: front to back 
direction gray scale intensity: light (higher-pressure amplitude, higher voltage) to dark (lower pressure 
amplitude, lower voltage).  Maximum pressure amplitude measured at the axial distance of 2.5 mm was 55 kPa 
(100 mW/cm2).  The pressure amplitude decreases by a factor of 3 dB at the axial distance of 8 mm. 
 
Two independent tests confirmed that the applicator does not produce inertial cavitation. 
The first test used aluminum foil to show pitting if inertial cavitation was present.  The 
second used a hollow cylinder hydrophone [110], coupled to a HP 8535A Spectrum 
Analyzer to display the acoustic spectrum for cavitation detection. This technique 
allowed both stable and inertial cavitation events to be determined.  Stable cavitation 
manifests itself by generation of subharmonics and its odd multiples of the fundamental 
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frequency [77], whereas inertial cavitation is characterized by white noise produced by 
the imploding of different diameter microbubbles [76].  In both experiments, the 
applicator showed no signs of inertial cavitation.  These outcomes are further 
corroborated by the literature data, where the inertial cavitation pressure amplitude 
threshold in water at 20 kHz was reported to be on the order of 100 kPa [111], and was 
dependent on the medium properties including cavitation nuclei sizes and bubble 
concentration. Clearly, this threshold is higher than the 55 kPa peak-to-peak pressure 
amplitude used here in the exposure studies described in the next section. 
Independent temperature testing was done using thermocouple measurements and it was 
determined that at the 100 mW/cm2 SPTP  intensity level used the applicator did not 
experience any self-heating and the temperature elevation in the immediate vicinity of the 
skin was below 0.5 °C even at prolonged - up to 45 minutes – exposure.  The paw 
temperature was recorded with a Testo 735 m (Testo AG, Germany) using a probe TC 
type K.  The probe was placed in contact with the paw of the mouse and the temperature 
recorded. 
RA carrageenan mice model and ultrasound exposure  
All experiments described below were performed at 20 kHz with the applicator operating 
at pressure amplitude of 55 kPa (peak-to-peak), with duty cycle of 50%, pulse repetition 
frequency of 25 Hz and total exposure time of 20 minutes.  The topical application of the 
drug contains 0.1% w/w betamethasone (Sigma-Aldrich, St Louis, MO, USA) in a water-
soluble polyethylene gel.  In controls, the same gel without the drug was used.   
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The anti-inflamatory drug betamethasone was chosen for this feasibility study because it 
represents the long acting corticosteroids with half-life of 36-54 hours [112]; hence a 
single dose used was adequate for the duration of the experiments described.  In addition, 
this compound is very potent and allows lower dose to be employed.  For example, 0.7 
mg betamethasone is equivalent to 29 mg of the short acting cortisol.  Finally, a lower 
volume (dose) of betamethasone was much easier to dissolve in the aqueous gel used as a 
coupling medium between the ultrasound applicator (Figure 49) and the animal’s (mouse) 
limb Figure 51. 
 
Figure 51: Mouse paw shown coupled to ultrasound transducer with ultrasound gel for topical drug application. 
 
Male ICR (CD-1®) (a Swiss mouse species) mice received topical administration of 
betamethasone combined with 20 min exposure to ultrasound (n=11), 1 hour prior to 
carrageenan injection.  The betamethasone/ultrasound treatment was performed before 
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the carrageenan induction due to the fact that an animal model was used - in this model to 
generate anti-inflammatory effect the compound/treatment has to be delivered prior to 
carrageen injection.  This is in contrast to the human patient’s situation: in a true diseased 
patient, the arthritis would already be present before treatment was administered.  
Overall, designing a protocol for therapy of inflamed joint, especially using animal 
models is not straightforward and deserves another dedicated study.  Control mice 
received topical administration of betamethasone (n=11), same 20 min exposure of US 
(n=11) or were left untreated (n=16).  Three (3) mg/kg carrageenan (Sigma-Aldrich, St 
Louis, MO, USA) was injected into the sub plantar area of the mice left hind paws.  Hind 
paw thickness was measured by JOCAL (Mitutoyo, Japan) calipers calibrated in 0.01 mm 
gradations before carrageenan injection and afterward at intervals of 1 h between each 
measurement.  Swelling was calculated as the difference between the thickness of the 
hind paw measured at each time interval and its size at zero time (before carrageenan 
injection).  The data were presented as the difference between mean thickness of the hind 
paw measured (by micrometer) at each time interval to its mean size at time zero (before 
carrageenan injection).  The caliper method to assess the degree of swelling was reported 
previously [113-114].  Although there are alternative quantitative methods capable of 
determining the swelling volume, in general they are much more complex: one potential 
method would require using 3 Tesla MRI [115]; another would be the use of a specialized 
measurement tool, such as a plethysmograph [116].  The caliper method was chosen here 
as it provided adequate information about relative swelling induced by the carrageenan 
and was considered sufficient for this feasibility study. 
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In vivo NIR imaging of paw inflammation in carrageenan-induced arthritis mice 
model  
To obtain an independent verification of the therapeutic effect of betamethasone 
formulation exposed to ultrasound, near infrared imaging scans were performed.  To this 
end, one hour after carrageenan injection, 10 nM of IRDye 800CW 2DG (LI-COR 
Biosciences, Lincoln, NE, USA) was injected intravenously into the tail of all groups of 
mice to measure glycolytic activity.  In vivo imaging of IRDye 800CW 2DG fluorescence 
in mice was performed with a LI-COR Biosciences small-animal imager Odyssey 
MousePOD® (LI-COR Biosciences, Lincoln, NE, USA) with the following conditions: 
resolution: 170–340 microns; pixel area: 0.03 mm2 (approximately 15–20 cells); quality: 
medium-low; focus offset: 1–3; channels: 800 nm; intensity: 1–3.  The mice received 
topical administration of betamethasone combined with 20 min ultrasound exposure 
(n=4), 1 hours prior to carrageenan injection.  Again, control mice received topical 
administration of betamethasone (n=3), 20 min ultrasound exposure (n=4) or were left 
untreated (n=4).  3 mg/kg carrageenan was injected into the sub-plantar area of the mice 
left hind paws.  One hour after the carrageenan injection, mice were injected with 10 
nmol of IRDye 800CW 2DG via the tail vein.  Images were taken 2 hours after the 
optical imaging probe, IRDye 800CW 2DG, injection.  The NIR images were processed 
using applied spectral imaging software, Spectral ViewTM (ASI, Migdal Ha’Emek, 
Israel) [117].  Intensity scale: red, green and blue denotes high, intermediate and low 
signal intensity respectively.  As already pointed out, the ultrasound exposure did not 
generate any thermal effect, hence it has not influenced the NIR imaging results.  
107 
 
However, it might be instructional to explain the informed choice of the above-mentioned 
dye (IRDye 800CW 2-DG) as the fluorescent agent.  
Briefly, the use of noninvasive NIR tool for visualization of the experimental data 
presented in Figure 53 was implemented by recognizing the fact that inflammation, 
similarly to the malignant tumors or cancers manifests itself as high metabolic activity 
and leads to elevated rate of glycolysis, even under aerobic conditions.  Thus, it is well 
suited for diagnosis purposes because the increased demand for glucose to fuel energy 
production in inflammation or in tumors translates to elevated expression and activity of 
cell surface glucose transport proteins, which can then be exploited for noninvasive 
imaging using glucose analogs.  These findings have been applied extensively in 
diagnostic clinical imaging employing positron emission tomography (PET), in which 
18FDG (2-fluoro-2-deoxyglucose) uptake is used to visualize tumor activity and location.  
Whereas the method is sensitive and quantitative and has been used in many pre-clinical 
studies, the use of 18FDG is impractical due to the specialized detection instrumentation 
required and relatively short (110 minute) half-life of the isotope.  Therefore, in this study 
the 18FDG radionuclide was replaced by near infrared fluorescent glucose analogue, 
IRDye 800CW 2-DG.  
Statistical analysis  
The data is presented as mean ± SD (Standard Deviation) of large series of independent 
experiments using different batches of 12-17 mice with carrageenan-induced arthritis in 
each experiment performed during a period of two years.  The experiments were repeated 
4 to 6 times.  All data were evaluated using the InStat statistics program (GraphPad, La 
Jolla, CA, USA).  Statistically significant differences between experimental groups were 
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determined by analysis of variance (ANOVA) with Bonferroni post-hoc test and 
considered significant when p<0.05. 
6.3: Results 
Anti-inflammatory effect of low frequency ultrasound combined with 
betamethasone 
Figure 52 presents the typical outcome of the experiment, summarizing the comparison 
between groups of 10-11 mice with carrageenan-induced arthritis, which received topical 
administration of betamethasone with and without ultrasound and respective controls.  
The results indicate that the administration of US with 25 mg betamethasone per kg mice, 
has a significant (p<0.05) therapeutic effect in comparison with the untreated group or 
either US alone or drug alone treated groups.  
 
Figure 52: Effect of low frequency US combined with betamethasone topical administration on carrageenan-
induced arthritis in a mice model.  Male CD1 mice received topical administration of 25 mg/kg mice 
betamethasone combined with 20 min exposure of low frequency US (n=11), 1 hour prior to carrageenan 
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injection. Control mice received topical administration of 25 mg/kg mice of betamethasone (n=10), 20 min 
exposure of low frequency US (n=10) or left untreated (n=11).  Three (3) mg/kg carrageenan was injected into 
the sub-plantar area of the mice left hind paws.  * p<0.05 compared no treatment group; ** p<0.05 compared to 
betamethasone treated group; *** p<0.05 compared to US treated group. 
 
Bio-imaging of the anti-inflammatory effect of low frequency ultrasound combined 
with betamethasone.           
The outcome of the quantitative and qualitative analysis of paw glycolic activity in 
carrageenan-induced arthritis in mice model is shown in Figure 53.  The infrared imager 
images were processed using Applied Spectral Imaging Software, Spectral View.  High 
intensity signal is shown in red; intermediate one in green and low is shown in blue. The 
NIR intensity was estimated at identical conditions for all mice.  The statistically 
significant differences (p<0.05) were found between combined ultrasound and 
betamethasone treated and untreated mice.  Interestingly, ultrasound treatment alone also 
provided a statistically significant (p<0.05) beneficial therapeutic effect when compared 
with untreated mice. 
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Figure 53: Near infrared fluorescent imaging of paw glycolic activity in carrageenan-induced  arthritis in mice 
model.  One hour after the carrageenan treatments previously described, mice were injected with 10 nmol of 
IRDye 800CW-2 DG via the tail vein. Images were taken 2 hours after the optical imaging probe, IRDye 
800CW-2 DG, injection via the tail vein. The infrared imager images were processed using Applied Spectral 
Imaging Software, Spectral View. Intensity scale: high intensity signal is shown in red; intermediate intensity 
signal, green; low intensity signal blue. The NIR intensity was estimated at identical conditions for all mice. * 
p<0.05 compared to no treatment group; ** p<0.05 compared to betamethasone treated group; *** p<0.05 
compared to US treated group. 
 
6.4: Discussion  
The present study indicates that low frequency (20 kHz), low intensity (100 mW/cm2) 
ultrasound can assist in topical delivery of anti-inflammatory RA drugs such as 
betamethasone.  In this study, an ultrasound-aided enhancement of betamethasone 
delivery was observed.  However, the proof of concept presented in this pilot study 
indicates the need for additional experiments systematically evaluating and optimizing 
the potential and efficacy of delivery.  
111 
 
Optical fluorescence imaging is increasingly being used to monitor tissue inflammation.  
Tissues under physiological conditions are labeled by 2DG dye at background levels.  By 
contrast, the elevated rates of glycolysis and glucose transport in the cells undergoing an 
inflammatory process provide a clearly visible fluorescent signal by comparison to non- 
inflamed tissue.  This approach was employed here to visualize the glycolytic activity on 
the paws of the carrageenan-induced arthritis model using 2-DG labeled with a near 
infrared probe [31, 100].  The outcome of these experiments further supports the 
significant therapeutic effects of combined ultrasound exposure and betamethasone 
topical application by comparison to topical drug treatment administration alone, as 
measured by glycolytic activity. 
The common clinical rationale for treating arthritic joints with drugs by intra-articular 
injection is that therapeutic concentrations of drug that can be attained in the joint 
compartment using a minimal total dose of betamethasone per joint thus resulting in 
minimal systemic exposure and toxicity.  For example, in a rat model of collagen induced 
arthritis [118] rats were administered intravenously a total dose of 52 mg/kg paclitaxel in 
six divided doses over ten days.  In another study [119] using the same model in rabbits, 
but using a slow release microsphere formulation, the dosage was 1.4 mg/kg.  Thus, the 
dose given to rabbits was approximately forty-fold lower than the systemic dose given to 
rats in the collagen induced arthritis model [119].  Furthermore, it has also been  shown 
that in healthy rabbits injected intra-articularly with either free methotrexate or controlled 
release methotrexate loaded microspheres, the plasma levels of methotrexate were 10-
fold lower in rabbits administered methotrexate microspheres compared to free 
methotrexate [120].  Wiggington et al. [121] showed that following a 5 mg intra-articular 
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dose of methotrexate solution in rheumatoid arthritis patients, synovial fluid levels were 
between 10 to 250-fold higher than serum levels over the first 24 h.  Similarly, in the 
present study the combination of ultrasound exposure with 25 mg betamethasone per kg 
mice are anti-inflammatory, at least in the short term, in comparison to drug treatment 
alone, which was not effective at the same dosage.  It is anticipated that a further analysis 
of the betamethasone release will be needed specifically in terms of pharmacokinetic 
evaluations of bethamethasone maintenance in the rat intra-articular synovial fluid.   
Despite the limitations (side-effects) of systemic administration of anti-rheumatic drugs, 
intra-articular delivery of disease modifying anti-rheumatic drugs has not attracted much 
interest so far because these drugs were not expected to remain in the joints long enough 
to be locally effective [122].  Delivery of drugs in joints using LFLI ultrasound promoted 
non-invasive drug delivery offers an exciting alternative for a novel intra-articular drug 
delivery method.  Although it is expected that by this approach less drug will be 
delivered, frequent administrations, which are less painful than injections, may provide 
the cumulative therapeutic dose.  The in vivo results presented here obtained in antigen-
induced acute arthritis are sufficiently encouraging to warrant further investigation in 
chronic models.  It is also conceivable that the protocol or paradigm rate of treatment is 
of importance and a rate, different than the one used here, would potentially further 
enhance the efficacy of the treatment.  
The following open questions remain following the present pilot study: i. Is the anti-
inflammatory effect seen here due to drug or the ultrasound (US)? ii. Can US get drug 
through the much thicker synovium of chronically, rather than acutely, inflamed joints; 
iii. Recognizing that betamethasone might not be the optimal drug, could other Cortico-
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Steroids (CS) be delivered by the same protocol? iv. As US delivery of CS can be 
administered more frequently than the intra-articular CS injections, might betamethasone 
then be preferable despite its shorter half-life?  v. Might ultrasound treatment result in 
unanticipated side effects?  With respect to that, our own analysis mentioned in the 
previous sections indicated that this is very unlikely at the exposure levels used in this 
work.  In addition, the review presented in [105] appears to suggest that the safety of the 
US assisted drug delivery is commonly accepted.  On the other hand, whereas the 
information provided in [105] indicates that the US assisted drug delivery is achievable, 
the biological end-points observed are not straight forwardly linked to all relevant 
ultrasound field parameters, such as its pressure amplitude or intensity, rate of delivery, 
frequency and total exposure time.  
Of particular interest is the mechanism(s) of action, as its knowledge would permit 
personalized treatment and healthcare cost reduction.  Ultrasonically assisted drug 
delivery mechanisms proposed in the scientific literature [105] include mechanical and 
thermal effects, heat generated as a result of the ultrasound energy propagating in lossy 
medium, such as skin tissue.  As confirmed by the thermocouple measurements described 
above, no temperature elevation was observed.  However, to facilitate comparison with 
diagnostic imaging conditions, the Thermal Index (TI - soft tissue case) was calculated 
using the guidelines of [94] indicating the TI value equal to 0.01.  The corresponding 
thermal dose index was calculated to be 0.237 [99].  With the  mechanical effects 
associated with inertial cavitation (sonophoresis) ruled out (see methods section), it is 
appropriate to reiterate that in the study described here the transdermal drug delivery was 
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most likely due to non-thermal, non-inertial cavitation effects such as acoustic radiation 
forces and stable cavitation.  
Acoustic radiation forces are mechanical stresses caused by acoustic energy interacting 
directly with cells [3], whereas stable cavitation indirectly induces mechanical stress by 
setting up acoustic streaming, which is a steady state fluid flow induced by time variable 
ultrasound energy [6, 123].  Additional mechanisms such as change in tissue architecture 
and change to cell membrane permeability might be considered.  However, it is also 
plausible that the changes in permeability are not necessarily due to the direct effect of a 
mechanical (ultrasound induced force) enforcement but encompass more intricate, multi-
step mechanism involving mechanoreceptors and chain-reaction on the cellular level.  It 
is further conceivable that the ultrasound mechanical stimulation activates cellular 
components such as microphages, fibroblasts or keratinocytes and it is their “cross-talk” 
that results in changes in cell membrane permeability.  Finally, the molecular weight of 
the drugs will need to be scrutinized and their chemical properties defined in order to 
qualify them as suitable candidates for transdermal delivery using the ultrasound 
exposure conditions considered in this work.  Whatever the mechanism responsible, this 
study underscores the potential for low frequency, low intensity, ultrasound assisted 
corticosteroid delivery in an acute model of RA in mice.  
Again, it may be useful to underscore that the pressure amplitude level of 55 kPa 
(corresponding to spatial-peak, temporal-peak intensity of 100 mW/cm2) and used in this 
study, rules out inertial cavitation and thermal effects as possible mechanisms of action, 
leaving radiation force and stable cavitation with associated second order acoustic 
phenomenon, such as acoustic micro-streaming [3].  In this context it is also conceivable 
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that the model (which does not require pre-existence of tiny air voids) proposed recently 
by [124] might be helpful to explain the results described.  Krasovitsky et al. [124] 
proposed cellular structure referred to as bilayer sonophore, which represented dynamic 
behavior of the two lipid bilayer membranes that was separated by hydrophobic volume. 
When exposed to an ultrasound field, this volume changes together with the 
compressional and rarefactional phases of the field.  Negative pressure amplitude allows 
the distance between the layers to increase whereas the positive one brings them closer to 
each other.  The modeling shows that the sonophore alone (without the need for existence 
of tiny air voids) is capable of transforming acoustic field into mechanical forces acting at 
the (sub) cellular levels. 
In conclusion, the findings of this study indicate that the combination of ultrasound 
exposure delivered with a special applicator together with betamethasone topical 
application are anti-inflammatory under acute conditions of therapy in contrast to drug or 
ultrasound treatments alone.  Quantitative bio-imaging of anti-inflammatory effect in the 
left paw of the carrageenan injected mice clearly confirmed the therapeutic effect of US-
betamethasone formulation.  
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Chapter 7: Conclusions and proposed future work 
As indicated earlier all aims of this or this thesis were achieved.  In this final chapter, the 
conclusions found completing of the specific aims that were addressed in this work are 
reiterated along with suggestions for proposed future work for each of these aims. 
Aim 1: FEA modeling for optimization of design 
Chapter 3 presented a systematic static finite element analysis that led to the optimization 
of a clinically relevant prototype for ultrasound assisted chronic wound healing and 
transdermal drug delivery applications.  The results of this research provided guidelines 
for optimization of the applicator design examined and indicated that consideration of 
future optimization studies could include different materials for further optimization (here 
described as highest displacement amplitude with minimum excitation voltage. 
Future studies could also be performed for optimization that do not just include different 
material properties but also, different embedding epoxies and application scenarios.  It is 
well known that the loading caused during application can result in different device 
behavior.  This loading is different depending upon the application and therefore several 
different application scenarios (similar to those discussed in aim 2) could be used during 
the optimization process.   
In addition to the various loading considerations, modeling of the transducer for 
optimization purposes could be expanded to include multiple elements.  These elements 
could be the same or different sizes, have the same or different spacing, all be in the same 
plane, or perhaps even be angled or contoured around a curve.  The possibilities are 
seemingly endless.  These different scenarios would enable a truly optimized device that 
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could be tailored to a very specific application or perhaps patient to patient changes.  
Although work on this has not been modeled with FEA, prototypes of some of the 
designs mentioned have been fabricated (Figure 54). 
 
Figure 54: The ultrasound applicator shown was a prototype designed with individually addressable elements 
that are housed in a silicone mold.   
 
Aim 2: Modeling of the acoustic forces to aid in the determination of mechanisms of 
action 
In Chapter 4, the FEA model of the ultrasound transducer developed in Chapter 3 was 
added upon, coupling it to in vitro testing fixtures (Petri dishes), which mimicked the 
experimental conditions.  Time domain analyses were then performed on the models 
118 
 
generating to obtain the complex (due to reflections) pressure versus time output.  This 
output was then utilized to estimate the forces that occur at tissue boundaries using the 
ultrasound applicator studied here.  
The results of these analysis showed that in the presence of air voids (gaseous pockets in 
the cells or bubbles on the surface in the coupling gel), forces on the order of milli-
Newtons are generated.  This is because the air-voids act as secondary sources in the 
ultrasound field and can cause additional radiation pressure and shear stresses at the 
tissue boundaries.  It in the absence of air voids, forces on the order of tens of nano-
Newtons are generated.  It is hypothesized that these forces are responsible for the 
cellular level mechanisms (such as cell proliferation and collagen production) involved in 
wound healing.   
These mechanisms are of much interest to all researchers involved in wound healing as 
they would provide a clearer understanding of how to maximize the efficacy of treatment.  
There is much more future work that needs to be done in order to determine these 
mechanisms.  Potential mechanisms have been narrowed through simulation and 
experimentation to effects elucidated by non-thermal, non-cavitational ultrasound.  
Knowing that small forces (on the order of milli-Newtons) are responsible for the 
beneficial effects stemming from the use of this ultrasound applicator, future work should 
be focused on investigating evaluating the specific cellular mechanisms caused by these 
forces.   
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Aim 3: Experimental validation of the ultrasound applicator’s efficacy in wound 
healing 
Chapter 5 contained experimentally obtained data related to the use of the ultrasound 
applicator as a means to accelerate wound healing.  Below the results and proposed future 
work related to this aim are discussed.  They are divided into in vitro studies and in vivo 
(human) studies.   
In vitro experiments 
In Chapter 5, in vitro experimental results were shown where two independent fibroblast 
experiments were performed using two different cellular assays measuring cell 
metabolism and proliferation (alamarBlue and BrdU, repectively).  These experiments 
and assays were used to determine the effect, if any, caused by the ultrasound on the 
cellular metabolism and proliferation.  The results were quite promising as they indicated 
low intensity (100 mW/cm2), low frequency (20 kHz) ultrasound can promote (increase) 
healing from the cellular level.  The safe levels of ultrasound used (the same as in the 
human study) did not cause thermal effects or damage to the fibroblasts during 
application.  Increased cellular metabolism and subsequent proliferation (shown using 
alamarBlue and BrdU assays, respectively) play vital roles in the wound healing process.   
Additionally, carefully designed (accounting for free field or standing wave conditions) 
and providing a direct link between the numerical value of the ultrasound field stimulus 
(pressure amplitude) and the biological end-point (e.g. collagen production for wound 
closing or – increased efficacy of drug effects) in vitro studies would be necessary to 
determine the effect of ultrasound on the many types of cells that could be potentially 
effected when using the ultrasound applicator.  Although it is well known that cells in the 
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human body respond differently to cells in a petri dish, it is hoped that these studies will 
help to hone in on the mechanisms of action.  In addition to fibroblast cells, future work 
could involve many more cell types such an epithelial cells, endothelial cells, and 
macrophages .  In order to determine more specifically how ultrasound influences the 
healing process, further analysis should be done of all of these cells types that are 
subjected to ultrasound including measuring protein concentrations such as collagen 
before and after application.  This would be extremely useful as collagen production 
leads to the extracellular matrix, which predominates the proliferative phase of wound 
healing.   
In vivo (human) experiments 
The in vivo human patient studies that were discussed in Chapter 5 show the combined 
results from pilot studies involving 25 venous ulcer patients (13 treated, 12 sham-treated) 
that demonstrated ultrasound treated ulcers at safe energy levels (100 mW/cm2, excluding 
inertial cavitation and thermal elevation) healed (statistically significantly) faster when 
compared to non-treated venous ulcers.  In addition to the venous ulcer studies that have 
been performed, there has also been a diabetic ulcer pilot study that was performed on 8 
patients (4 treated, 4 sham-treated) with the same ultrasound parameters that were used in 
the venous ulcer study.  This study has even more promising results (due to small study 
size it is difficult to draw conclusions), where the treated group healed up to 5 times 
faster than the sham-treated group.    
Furthermore, no adverse events have been observed throughout any of the in vivo studies 
and the tether-free, 20 kHz battery powered ultrasound applicator can be comfortably 
worn by patients (there have been no complaints to date).  With the anticipated future 
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advances in battery technology, these devices could be used at home between dressing 
changes with minimal charging (once per day).  This would further facilitate an active 
wound treatment compared with traditionally passive (compression and debridement) 
wound therapies currently used in clinical practice.   
The initial scope of the future work regarding the treatment of chronic venous- and 
diabetic ulcers will be to increase the number of patients to improve the reliability of the 
statistical analyses that have been performed.  Although there exist significant differences 
between the means of the treated and control groups for both of these patient populations, 
the statistical power (the chance of repeatedly achieving the same significant results) of 
the venous ulcer study was only 60% and there was not enough data in the diabetic study 
to definitively calculate the power accurately.  The FDA has requirements for statistical 
power of 80% for a study in order to achieve approval for medical device efficacy.  This 
would require a minimum of 30 more patients (15 treated, 15 control) in the venous ulcer 
population and approximately the same for the diabetic population. 
Increasing the sample size will help to identify if the currently used ultrasound 
parameters are significantly improving the healing time of chronic wound patients.  
However, additional future work with humans will be necessary to help identify the 
mechanisms by which the ultrasound is causing an effect.  Current approaches for 
determining these mechanisms include collection of debrided tissue from the treated 
wounds and identifying various gene expressions from the different cell populations (e.g. 
macrophages) that exist in this debrided tissue.  This will help to identify what cell 
populations the ultrasound is having an effect on and perhaps what that effect is.   
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Finally, expanding the potential patient population to the treatment of chronic pressure 
ulcers is also possibility.  Although, the underlying etiologies of chronic wounds are 
vastly different (as is the case for venous and diabetic ulcer), it is hypothesized that this 
ultrasound applicator could have potential benefits, such as accelerated healing, in this 
type of wound too.       
Aim 4: Experimental validation of improved transdermal drug delivery using the 
ultrasound applicator  
Chapter 6 discusses, in detail, a drug delivery experiment using the ultrasound applicator 
that was described here.  During the drug delivery experiment the same ultrasound 
parameters were used as those in the chronic wound healing studies, although only single 
element applicator was employed.  This was because the applicator was being used on the  
mouse’s paw, which is somewhat smaller than the area of a single element as can be seen 
in Figure 51.  Briefly, in this experiment, inflammation was induced in mice’s paws and 
application of a topical drug (betamethasone) and ultrasound exposure were used 
separately and in conjunction to identify the effects the treatments had on inflammation.  
It was shown that the combinatory effects of betamethasone with ultrasound application 
showed a significant reduction in paw volume when compared with the other groups.  
This pilot study verified that the ultrasound applicator used in the study is capable of 
assisting in the delivery of topical drugs. 
Future work aiming at the syringe-free, non-invasive, ultrasound-assisted drug delivery 
would have to address identification of the mechanisms of action (briefly discussed in 
Chapter 6) and figuring out the pharmaceutical parameters of the drugs , such as lipo- or 
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hydrophilicity, molecular weight, molecular structure and alike that would enable their 
transdermal delivery.   
Closing Remarks 
On the mind of every researcher in the field of therapeutic ultrasound are the same few 
words: “what are the mechanisms of action?”  This simple - “how does it work”- question 
– turns out to be a very complicated one and the reply to it is certainly not obvious.  
However, both the results of the in vitro experiments described here in Chapter 5 and 
those in the literature that unequivocally identify the input stimulus (ultrasound wave) in 
a quantitative way with the biological end point seem to point out that the explanation 
requires in depth understanding of physical-chemical phenomena induced by the 
stimulus, which most likely leads to cellular, chemical response. This response is 
triggering of the activation of the cells - for instance the fibroblasts examined here to 
generate collagen (an indispensable component in tissue healing or repair process) is 
plausible. It is the recommendation of the author that interdisciplinary teams study such 
effects.  These teams should include individuals with backgrounds in (molecular) 
biology, physiology, physics, and engineering.  The author is convinced that only such 
close collaboration, with careful in vitro and in vivo experiment design and testing, can 
gradually produce an answer to the “how does it work” query.  
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Appendix A: MATLAB constants Wrenn modified Rayleigh-Plesset Equation 
% constant assumptions of the model 
surface_tension = 0.073; 
density = 998; %[kg/m^3] density 
kinematic_tension = 1.0e-6; %[m^2/s] 
  
% speed of sound in water 
speed_of_sound = 1540; %[m/s] speed of sound 1480-water 1540-tissue 
  
% vapor and static pressure assumptions 
vapor_pressure = 2.34e3; %[Pa] 
static_pressure = 1.01325e5; %[Pa] 
  
% heat capacity ratio of material (polytropic exponent) 
heat_capacity_ratio = 1.4; 
 
% shell parameters 
mu = 0.001; %[Pa s] viscocity of outside medium 
epsilon = 1e-9; %[m] shell thickness 
chi = 1.1; %[N/m] shell elastic modulus 
mu_sh = 0.63; %[Pa s] shell viscosity 
ks=7e-6; %[Pa*s]surface dilational viscosity value from wrenn paper 
Ka = 0.050; %[N/m] area expansion modulus (wrenn) value from paper 
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Appendix B: MATLAB constants Krasovitski-Kimmel model 
DSF=0.2000e-08;     %THICKNESS OF MEMBRANE,m 
ROS=0.1056e+04;     %DENSITY OF MEMBRANE, kg/(m**3) 
AKS=0.1200;         %STRETCH STIFFNESS OF MEMBRANE, Pa*m 
ANU=0.2500;         %POISSON'S COEFFICIENT OF MEMBRANE,  
ATAS=0.5000e-01;    %DYNAMIC VISCOSITY OF MEMBRANE, kg/m/s 
DD0=0.1400e-08;     %INITIAL GAP UNDER MEMBRANE,m 
A0=0.2500e-06;      %MEMBRANE RADIUS, m  
HSMIN=0.5000e-03;   %INITIAL CENTRE DEVIATION, DIM-LESS  
AR=0.1000e+06;      %ATTRACTION/REULSION PRESSURE COEFFICIENT, Pa 
SI=0.1400e-08;      %ATTRACTION/REULSION EQUILIBRIUM DISTANCCE, m  
AM=0.5000e+01;      %EXPONENT IN REPULSION TERM  
AN=0.3300e+01;      %EXPONENT IN ATTRACTION TERM   
ROL=0.1056e+04;     %DENSITY OF LIQUID,kg/(m**3) 
DAB=0.2000e-09;     %DIFFUSION COEFFICIENT WATER -AIR, m**2/s 
CIA=0.6930e-03;     %INITIAL MOLAR AIR CONCENTR. IN WATER,mol/m**3 
AK=0.1000e+01;      %POLYTRPICAL CONSTANT.OF AIR 
GAM1=0;             %SURFACE TENSION LIQUID/MEMBRANE COEFF, N/m 
GAM2=0;             %SURFACE TENSION AIR /MEMBRANE COEFF, N/m 
AMU=0.1000e-02;     %DYNAMIC VISCOSITY OF WATER, kg/m/sec 
AS=0.1500e+04;      %SPEED OF SOUND IN LIQUID, m/sec 
AKA=0.1460e+09;     %HENRY CONSTANT OF AIR, Pa*m**3/mol 
BR=0.8314e+04;      %UNIVERSAL GAS CONSTANT, J/mol/K 
P0=0.1000e+06;      %STATIC PRESSURE IN LIQUID, Pa 
T0=0.2930e+03;      %TEMPERATURE OF LIQUID,.K 
FF=0.1000e+07;      %ULTRASOUND FREQUENCY,Hz 
ACO=0.2000e+01;     %PRESSURE AMPLITUDE, DIMENSIONLESS 
BET=0.1570e+01;     %INITIAL PHASE 
EFE=0.2718e+01;     %NEPER NUMBER E 
 
 
 
 
